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The purpose of this study was to determine whether branched-chain amino acid 
(BCAA) supplementation attenuates indirect indicators of muscle damage, lowers ratings 
of perceived exertion, and improves aerobic performance as compared to an isocaloric, 
carbohydrate (CHO) beverage or a non-caloric placebo beverage. 
 Nine, untrained males (VO2 max 36.26   2.23 ml/kg/min) performed three 90-
minute cycling bouts at 55% VO2 max followed by a 15-minute time trial.  Metabolic 
data was collected every 15 minutes during the steady-state ride, and indirect muscle 
damage markers were assessed pre, post, 4-hours, 24-hours, and 48-hours post-exercise.  
Pre and post-exercise concentrations of the BCAA and glucose were also recorded.  All 
blood markers were adjusted for plasma volume shifts. 
 There were no differences in dietary intake between trials for 3 days prior to 
exercise.  Creatine kinase concentrations were significantly lower after the BCAA trial as 
compared to the placebo trial at 4, 24, and 48-hours post-exercise, as well as the CHO 
beverage at 24-hours post-exercise.  Creatine kinase was lower in the CHO trial at the 24- 
and 48-hour time points as compared to the placebo trial.  Lactate dehydrogenase 
concentrations were elevated in the placebo trial at 4-hours as compared to the BCAA 
trial.  As compared to the alternate trials, ratings of perceived soreness were lower at 24-
hours post-exercise, leg flexion torque was higher at the 48-hour time point, and plasma 
concentrations of the BCAA were elevated following the BCAA trial.  Time-trial 
performance was improved in the CHO trial, and ratings of perceived exertion were 
lower at 75 and 90-minutes of exercise in the BCAA trial as compared to the placebo 
trial. 
 There were no significant condition x time differences for leg extension torque, 
VO2, ventilation, heart rate, RER, or energy expenditure.  In addition, there was no order 
effect for creatine kinase, lactate dehydrogenase, leg flexion/extension torque, ratings of 
perceived soreness, or time trial performance. 
The present data suggest that BCAA supplementation attenuates muscle damage 
during prolonged endurance exercise in unfit, college-aged males, but does not affect 
time trial performance.  CHO ingestion improves time trial performance and attenuates 
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 Since the dawn of sport athletes have employed a myriad of nutritional strategies 
in order to enhance performance.  From ancient Greeks' and Romans' use of deer liver 
and lion heart to the alcohol use in the late 19th Century, athletes often mistakenly 
believe the food products they consume for extra speed or strength are effective.9 In 
addition to the placebo effect associated with all dietary supplements, aggressive and 
often misleading advertising leads the athletic population to believe in the efficacy of a 
particular supplement whose use may or may not be of any benefit. 
 Following the formation of the "central fatigue" hypothesis by Newsholme et al. 
(1987), investigations into the potential ergogenic effects of the branched-chain amino 
acids (BCAA) began in 1991, but no formal conclusions can yet be drawn.18, 22, 23, 25, 77, 97, 
109 Avenues for BCAA supplementation to enhance performance beyond their potential 
influence upon tryptophan entry into the brain, such as a beneficial effect on protein 
metabolism and attenuation of muscle damage during endurance exercise, have recently 
emerged but have not been tested extensively.42, 127 
 Exercise-induced muscle damage, first described by Hough in 1902, is 
characterized by delayed-onset muscle soreness, Z-line streaming, general myofilament 
disorganization, impaired maximal force production, and the appearance of muscle 
proteins in the blood.11, 37, 82 Unfortunately, strategies to reduce the amount of damage a 
muscle incurs during exercise are relatively non-existent.  However, BCAA ingestion 
during endurance exercise decreases the appearance of muscle enzymes in the blood as 
compared to a non-caloric placebo, which indicates a potential reduction in muscle 
damage.42  
 BCAA supplementation may help prevent muscle damage during aerobic exercise 
due to leucine's potential regulatory role in protein synthesis, altered hormone levels, and 
increasing the amino acid content in free pools which may prevent the need for protein 
degradation.6, 7, 28, 32, 68, 147, 148 Therefore, the purpose of this study is to investigate 
whether BCAA supplementation prevents muscle damage during prolonged endurance 
exercise as compared to an isocaloric carbohydrate beverage.  This will ensure that the 
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attenuation of damage is not simply due to energy intake, a matter that cannot be 
confirmed through previous research.42, 127 
 
Statement of the Problem 
 Hikida et al. (1983) reported evidence of muscle damage in pre-race biopsies of 
marathon runners.80 In terms of aerobic performance, supplementation is usually focused 
on whether it will improve competition performance.  It is now evident that the focus 
must also be directed upon training as well as the competition.  Considering that athletes 
may exhibit significant signs of muscular damage pre-race, attenuating the damage 
during the general training cycle through supplementation may encourage a better chance 
for optimal performance during the competition.  Due to methodological drawbacks, 
namely the lack of isocaloric comparisons, no research has been able to confirm whether 
BCAA supplementation decreases muscular injury during prolonged endurance exercise 
as compared to a non-amino acid containing isocaloric beverage.  Additionally, questions 
remain as to whether BCAA supplementation has any potential for aiding aerobic 
performance.   
 
Research Hypotheses 
The following hypotheses will be tested: 
Specific Aim 1: To determine whether BCAA supplementation attenuates muscle damage 
induced by prolonged endurance exercise as compared to an isocaloric beverage without 
amino acids or a non-caloric placebo. 
 Hypothesis 1a: A BCAA-containing beverage decreases post-exercise serum 
levels of creatine kinase (CK) and lactate dehydrogenase (LDH) as compared to 
the isocaloric and placebo beverages. 
 Hypothesis 1b: BCAA supplementation attenuates the loss of maximal voluntary 
leg flexion and extension contraction torque post-exercise as compared to the 
isocaloric and placebo beverages. 
 Hypothesis 1c: BCAA supplementation lowers post-exercise ratings of perceived 
soreness as compared to the isocaloric and placebo beverages. 
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Specific Aim 2: To determine whether BCAA supplementation has any influence over 
aerobic performance or metabolism as compared to the alternate beverages. 
 Hypothesis 2a: A BCAA-containing beverage decreases the amount of time it 
takes to complete a loaded time-trial as compared to the isocaloric and placebo 
beverages. 
 Hypothesis 2b: BCAA supplementation attenuates ratings of perceived exertion 
throughout a prolonged endurance exercise trial as compared to the isocaloric and 
placebo beverages. 
 Hypothesis 2c: BCAA supplementation has no effect on VO2, ventilation, heart 
rate, respiratory exchange ratio, or lactate levels throughout a prolonged 
endurance exercise trial as compared to the isocaloric and placebo beverages. 
 
Assumptions 
This study will be conducted based on the following assumptions: 
 Assumption 1: All subjects understand the exercise and dietary restrictions of the 
study, and adhere to these guidelines honestly. 
 Assumption 2: Subjects put forth a maximal effort during the loaded time-trial. 
 Assumption 3: The enzymes measured from the blood are of skeletal muscle 
origin. 
 Assumption 4: Randomization of beverage assignment controls the confounding 
training effect that may take place over the course of the experimental trials. 
 
Limitations 
The current study has the following limitations: 
 Limitation 1: Muscle damage will be measured indirectly due to the invasive 
nature and potential inaccuracies of direct measurements. 
Limitation 2: Statistical power will be restricted due to sample size limitations.  
However, a sample size sufficient to obtain a power equal to or greater than 0.8 





VO2 max: The maximal amount of oxygen that can be used during the performance of 
exercise utilizing a large muscular mass.2 
Muscle damage:  Muscle fiber injury that appears as a consequence of repetitive exercise 
or specific traumatic muscle injury such as mechanical strain.11 
Torque:  The effectiveness of a force in causing a rotation.75  
Peak torque:  The maximal amount of torque that can be produced in a given trial. 
Isokinetic dynamometry:  A method used for the assessment of dynamic muscle function 
in which torque is measured while movement velocity is controlled.75 
"Loaded" time trial:  An exercise bout preceded by prolonged steady-state exercise to 
reach a predetermined distance in the shortest duration possible or to cover maximal 
distance within a predetermined duration. 
Delayed-onset muscle soreness (DOMS):  Discomfort or pain originating from the 
skeletal muscles that lasts from 24-hours to 7-days following muscular exertion, 
particularly if the muscular action is unfamiliar.10 
Exertional Rhabdomyolysis:  The release of intramuscular proteins into the blood as a 
result of exercise-induced muscle damage.139 
 
Significance of the Study 
 This study is expected to produce unique and needed knowledge in the field of 
sport nutrition.  In addition to elucidating whether BCAA supplementation plays a role in 
aerobic performance and the prevention of muscle damage, these results will also provide 
additional insight as to the role leucine may play as a regulatory compound in protein 
metabolism.  To this point, the data indicating leucine's unique role in this process is 
almost solely from animal subjects. 
 If it can be shown that BCAA supplementation does help alleviate muscle damage 
as compared to a non-protein energy source, there will be implications for populations 
that suffer from chronically high levels of muscle damage other than endurance athletes 
(e.g., most forms of muscular dystrophy).  If continuous supplementation can even 
slightly reduce the rate of damage among this diseased population, functionality may be 
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significantly maintained and quality of life improved for longer periods than would 
































REVIEW OF LITERATURE 
 
Introduction 
Leucine, isoleucine, and valine comprise the branched-chain amino acids 
(BCAA).154 Although the majority of energy required for a sustained rate of muscular 
contraction comes from the aerobic metabolism of lipid and carbohydrate, BCAA 
oxidization can contribute energy as well as give rise to TCA-cycle anaplerotic additions 
or intermediate subtractions [note: for the remainder of this review, the term “muscle” 
will refer to skeletal muscle unless otherwise noted].77 BCAA utilization may also be 
highly involved in the phenomenon known as "central fatigue."17 Although the majority 
of evidence suggests that dietary supplementation of BCAA does not affect performance, 
their intake may play a role in the attenuation of muscle damage during prolonged 
endurance exercise.18, 22, 23, 25, 42, 77, 97, 127 
 
BCAA as Fuel Source and Modifier of Oxidative Metabolism 
Although the vast majority of amino acids (AA) ingested are immediately 
transported to the liver and are oxidized, the BCAA escape splanchnic oxidation due to 
low BCAA aminotransferase activity.81 Consequently, BCAA and glutamate account for 
over 90% of muscle AA uptake.154 Their catabolism during exercise, made possible by 
high levels of branched-chain keto acid dehydrogenase (BCKAD) within the muscle, has 
been demonstrated through various human studies.154, 155 During exercise BCAA are 
released from the splanchnic bed (liver, gut) and taken up by muscle in greater amounts 
than at rest.4 The activity of BCKAD, the rate-limiting enzyme in BCAA metabolism, is 
increased with exercise duration (as glycogen levels are diminished) and nutritional status 
playing a regulatory role.156, 157 As expected, prior muscle glycogen depletion results in 
increased whole-body protein utilization.151  
 In regards to stable isotopic tracer methodology, the degree of BCAA contribution 
to energy expenditure is not clearly defined.  Wagenmakers (1998) hypothesized that the 
free leucine pool is diminished during exercise due to oxidation by the contracting 
muscle.155 Since the leucine pool changes during exercise, the assumption of a constant 
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pool size for an isotopic tracer is violated.  Therefore, the use of leucine to determine 
whole body protein flux may not be an appropriate method.155 However, phenylalanine 
and urea tracers consistently show no increase in whole body protein degradation during 
6 hours of moderate intensity aerobic exercise, whereas leucine tracers show increases in 
degradation at intensities as low as 30% VO2 max.118, 155 Taking into account the issues 
with leucine tracers previously mentioned, we can conclude that prolonged exercise 
between 30-50% VO2 max most likely causes minimal protein breakdown.77 
 Leucine, isoleucine, valine, asparagine, aspartate, and glutamate are the only AA 
metabolized in resting muscle.154 These AA are the sources of the amino groups and most 
likely the ammonia required to synthesize alanine and glutamine both of which are 
released in large levels in the postabsorptive state.  Only leucine and a portion of 
isoleucine are oxidizable; the other AA carbon skeletons are used for synthesis of 
glutamate and TCA-cycle intermediates.25, 77, 154 
 
Carbon Drain 
 The first step in BCAA breakdown is transamination; the amino group of leucine 
is accepted by  -ketoglutarate, forming glutamate.  This creates a carbon drain on the 
TCA cycle which is compensated by the alanine aminotransferase reaction when there 
exists an adequate supply of pyruvate (i.e. when glycogen or a high supply of glucose is 
available).154 When pyruvate is not readily available, the oxidation of leucine could 
theoretically lead to an attenuation of TCA cycle flux and consequently reduced ATP 
turnover.  This leads to the hypothesis that BCAA supplementation may actually promote 
fatigue in subjects low in glycogen. 
 McArdle's disease involves a deficiency of myophosphorylase; therefore, this 
diseased population cannot utilize muscle glycogen for energy.  Since the pyruvate 
contribution from glycogen will be void, the alanine aminotransferase reaction will not be 
able to fully compensate for the carbon drain caused by leucine oxidation.  Indeed, 
BCAA supplementation given to McArdle's disease patients decreases aerobic 
performance and leads to increased heart rate and plasma ammonia.158 However, in non-
diseased subjects with reduced muscle glycogen content BCAA supplementation does not 
affect performance of a graded incremental exercise test.153 
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The Central Fatigue Hypothesis 
 Fatigue can be defined centrally or peripherally.  Peripheral fatigue refers to the 
inability to maintain a rate of excitation-contraction coupling that originates within the 
muscle itself.  In contrast, central fatigue originates in the central nervous system.  5-
hydroxytryptamine, commonly known as serotonin, increases during exercise and has 
been hypothesized to contribute to central fatigue.24, 34 Studies making use of 
pharmacological agents have given support to serotonin's contribution to fatigue.  In 
animal models, serotonin agonist administration hinders running performance, whereas 
serotonin antagonists have the opposite effect.14, 15 In human subjects, the administering 
of a serotonin reuptake inhibitor reduces time until exhaustion during cycle ergometry.161  
 Serotonin levels in the brain are affected by the blood concentration of 
tryptophan, the precursor to 5-hydroxytryptophan which converts to serotonin.  Since the 
enzymes involved in the synthesis of serotonin have high capacities, the transport of 
tryptophan across the blood-brain barrier is the rate-limiting step.55 Tryptophan competes 
with other large, neutral amino acids (primarily the BCAA) for entry into the brain.  
Therefore, BCAA concentrations in the blood can significantly affect quantities of 
tryptophan crossing the blood-brain barrier.116 It should also be noted that an increase in 
free fatty acid levels as seen during exercise increases the amount of tryptophan unbound 
to albumin ("free"), thereby increasing the amount that enters the brain.33 
 Research has confirmed that during prolonged endurance exercise, the free 
tryptophan/BCAA ratio is altered in favor of tryptophan entry into the brain.  Blomstrand 
et al. (1997) demonstrated a 3.6   0.2% increase in the free tryptophan/BCAA ratio 5 
minutes after an 80 minute cycling protocol at 70% VO2 max.  The ratio changes are also 
significantly different from resting conditions at 60 and 80 minutes of exercise (1.9   
0.1% and 2.1   0.1%, respectively).21 In 1988, Blomstrand et al. also reported significant 
free tryptophan/BCAA ratio increases post-marathon as compared to pre-race conditions 
in 22 runners (5.0   0.3 vs. 1.6   0.1, respectively).19 Likewise, the ratio is also elevated 
after a 30 km running race (3.9   0.4 post-race vs. 1.5   0.1 pre-race).78 
  Therefore, increasing the BCAA concentration in the blood could lead to less 
tryptophan entry into the brain and consequently delay the onset of fatigue or increase 
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performance times.  BCAA ingestion is a viable method since it causes a swift rise in 
their levels because of low BCAA transferase activity in the liver.81 Blomstrand et al. 
(1991) observed an improvement in marathon performance times with ingestion of 16 
grams of a BCAA solution as compared to a placebo.22 However, this improvement is 
only seen in "slower" runners (those who completed the marathon between 3 hours and 5 
minutes and 3:30).  Running times were taken at 10.5 km, 20.5 km, and at the end of the 
race.  Performance was determined by the time-ratios for the two distances (e.g. the time 
to cover (42.4 km -10.5 km) / the time at 10.5 km).  The "slower" supplemented group 
shows faster times for both the 10.5 km and 20.5 km time-ratios (3.18   0.14 vs. 3.27   
0.17 h and 1.15   0.054 vs. 1.18   0.070 h, respectively).  The author's rationale for the 
lack of improvement in supplemented "faster" runners at the same distances (3.21   0.14 
vs. 3.20   0.12 h and 1.14   0.052 vs. 1.13   0.051 h) was that they might be highly 
resistant to both central and peripheral fatigue, ultimately making them less sensitive to 
the potentially ergogenic effect of BCAA ingestion.22 However, this study contains three 
major design flaws.  One, the placebo and control groups should have been matched for 
previous performance.  Pre-race nutritional data was also not kept and, therefore, not 
matched.  Additionally, taking a single marathon time to define "fast" and "slow" runners 
may not have been appropriate either. 
 Subsequent studies have not been able to demonstrate the ergogenic effect of 
BCAA supplementation.  Varnier et al. (1994) infused BCAA into 6 males with a 
reduced muscle glycogen content during a 90-minute cycling trial.153 At intensities at or 
above 75% VO2max, average lactate concentrations are higher (4.97   0.41 mmol/L) in 
the supplement group than the placebo group (3.88   0.47 mmol/L).  No significant 
differences are reported in total work performed or heart rate between the two groups, 
although no specific data are given.  As previously mentioned, this study also suggests 
that the carbon drain placed on the TCA cycle from the oxidation of leucine, which 
would not be readily compensated with low glycogen levels, may not be practically 
significant in non-diseased populations.153 
 Blomstrand et al. (1995) reported no significant performance differences in work 
between non-isocaloric placebo, carbohydrate (CHO)-supplemented, and CHO+BCAA-
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supplemented groups (787   16, 808   18, and 808   24 kJ respectively) during 60-
minutes of exercise at approximately 75% VO2max.18 During the 20-minute time trial 
following this steady-state ride, work performed was once again not significantly 
different between groups (231   11 kJ for placebo, 263   13 kJ for CHO, and 264   11 kJ 
for CHO+BCAA).18 Madsen et al. (1996) also compared supplementation with either a 
placebo, glucose, or glucose+BCAA beverage during a 100 kilometer cycling trial in elite 
(VO2 max 63.1   1.5 ml/kg/min) athletes.98 Time to complete the trial does not differ 
between groups (159.8   3.7, 160.1   4.1, and 157.2   4.5 minutes, respectively).98 
 A 1995 study by Van Hall et al. suggests that either tryptophan levels in the blood 
may not significantly affect serotonin levels in the brain or that serotoninergic activity in 
the brain has no bearing on fatigue.150 A tryptophan supplement significantly raises blood 
tryptophan concentrations during exercise (47   6  mol/L at rest vs. 304   61  mol/L at 
exhaustion), whereas placebo and BCAA-supplemented groups does not increase blood 
tryptophan.  In fact, both BCAA-supplemented groups succeed in reducing blood 
tryptophan (44   5  mol/L at rest vs. 40   6  mol/L at exhaustion for the low BCAA 
dose; 45   10 vs. 38   7  mol/L for the high BCAA dose).  However, the groups do not 
differ in time to exhaustion during a cycling bout.150 Tryptophan ingestion prior to 
exercise (1.2 grams over 24 hours) also has no effect on treadmill running time to 
exhaustion.141 This indicates that blood tryptophan concentrations may not influence 
serotoninergic activity.  Alternate explanations include an increased efflux of serotonin 
counterbalancing the influx, or increases in intraneuronal monoamine oxidase activity 
which results in serotonin degradation.150 There is also the implication that serotonin does 
not influence fatigue, but this is widely contradicted by research.14, 15, 161 
  
Etiology of Muscle Damage 
 The term “muscle damage” typically refers to exercise-induced muscle cell and 
extracellular matrix injury that can ultimately impair normal function.  The mechanical 
strain and metabolic hypotheses encompass the two primary explanations for the origin of 
the injury.11 
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 As early as 1902, Hough concluded that muscle damage and the soreness that it 
causes is a direct result from microtears in the muscle fibers or other connective tissues.82 
In the century that followed, histological and biochemical evidence confirms in both rat 
and human models that muscular damage is invoked by certain exercise protocols, in 
particular eccentrically biased ones.  Friden et al. showed Z-line streaming and altered 
organization of myofilaments in humans at the A-band 48 and 168 hours after a repeated 
stair descent protocol.64 Subsequent studies find that the extent of visible damage from 
biopsy samples is greater 24-48 hours post-exercise than those taken immediately post-
exercise.65, 107 The majority of work in the early-mid 1980s utilizes the muscle biopsy 
procedure.  It has more recently been demonstrated that the biopsy procedure can itself 
cause muscle damage similar to what is described as exercise-induced damage (i.e. 
extracellular matrix damage, local neutrophil and macrophage infiltration), and therefore 
it cannot be concluded that exercise induces muscular damage on the merits of this 
technique alone.101, 125 However, with the use of other techniques such as MRI, 
measuring maximal voluntary and involuntary contraction force, and quantifying muscle 
enzyme levels released into the bloodstream as a result of rhabdomyolysis (e.g. creatine 
kinase, lactate dehydrogenase, carbonic anhydrase III, aspartate isoenzyme II), it can be 
confirmed with high confidence that muscular damage is incurred by certain exercise 
protocols.37 
 The hypothesis that suggests muscle damage is the result of mechanical strain is 
supported by animal and human data showing that performing eccentric contractions at 
longer muscle lengths results in greater loss of force post-exercise.84, 113, 145 A greater 
degree of stretch implies a larger strain which in turn damages the sarcomere, 
cytoskeleton, and extracellular matrix.  Although it is unknown why eccentric muscle 
actions induce greater damage than concentric ones, two hypotheses have been proposed 
to explain the phenomenon.  When working against a similar resistance, the EMG 
(electromyography) activity within the muscle is less during an eccentric contraction as 
opposed to the concentric.16 This implies that fewer fibers are being recruited and 
consequently would be under greater tension during eccentric work thus being more 
susceptible to damage.  Morgan (1990) proposes the “popping-sarcomere” hypothesis 
suggesting that when either high or sudden strain is induced, a non-uniform stretching of 
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sarcomeres occur.104 This would place particular sarcomeres under greater tension and 
thus cause more damage. 
 The metabolic hypothesis of muscle damage implies that muscle damage results 
from environments in which ATP demand exceeds ATP production.  Due to ATP-
dependent calcium pumps, a reduced ATP concentration in the cell could lead to 
excessively high calcium levels resulting in cell death.  Studies that have examined 
muscle ischemia (which would cause abnormally low ATP levels) found that the damage 
induced has a similar time course and nature as damage caused by strain.93, 100 In 
addition, Tiidus and Ianuzzo (1983) observed that exercise intensity is proportional to the 
degree of damage induced.146 This indirectly suggests that greater damage is caused when 
ATP demand is higher.  However, there is a large amount of evidence to refute the 
metabolic hypothesis.  During submaximal exercise, ATP concentrations are held 
approximately at resting levels (i.e. supply is able to meet demand).11 This would be a 
common situation in many endurance events that have been shown to cause muscle 
damage.31, 42, 95 In addition, energy use during eccentric contractions is lower than during 
concentric contractions even though the extent of damage caused is greater.16 This 
evidence suggests that although the metabolic hypothesis may be valid, its contribution 
alone is not sufficient to explain the entire etiology of exercise-induced muscle damage. 
 
Methods of Determining Muscle Damage 
 There are currently only two methods for direct assessment of muscle damage: 
muscle biopsy and magnetic resonance imaging (MRI).  As previously stated, the 
technique of muscle biopsies may inflict damage to the muscle making it difficult to 
distinguish between exercise-induced damage and biopsy-induced damage.101, 125 More 
importantly, biopsies use a small sample to quantify damage throughout an entire muscle, 
greatly increasing the possibility of overestimating or underestimating the overall 
damage.  Alterations in T2 relaxation time using MRI are believed to indicate edema 
(would be a byproduct of damage) in the muscle.  However, it is still uncertain what truly 
produces alterations in MRI signal intensity.144 
 Indirect measures of muscle damage are far more frequently used in the study of 
exercise-induced muscle damage.160 According to Warren et al. (1999), 73% of human 
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studies reviewed concerning muscle damage use muscle soreness as a measure; 52% used 
blood proteins; and 50% used maximal voluntary contraction (MVC) force/torque.160 All 
three of these methods have positive and negative attributes regarding the determination 
of muscle damage. 
 Delayed-onset muscle soreness (DOMS) peaks 24-48 hours post-exercise, and 
may last up to 7 days post-exercise.38, 52 Intensity of soreness is dependent upon activity 
with eccentrically biased exercises producing the highest values of soreness; however, the 
time course is consistent between exercise modes.29, 39, 46, 83, 99, 108, 121, 123, 128 DOMS can be 
measured subjectively on a 10-point scale or a 6-point scale, but can also be examined 
more objectively by measuring force applied to a muscle at pain threshold.51, 160 
Unfortunately, DOMS has not correlated well with alterations in muscle function.122, 128, 
160 
It is relatively unclear as to what causes the pain of DOMS.  Crenshaw et al. 
(1994) demonstrated that damage-induced edema (specifically intramuscular fluid 
pressure and swelling) contribute to feelings of soreness.46 However, the time course of 
peak fiber swelling and peak soreness are not consistent (soreness peaks up to 8 days 
before swelling).38, 122 Nosaka et al. (1996) hypothesized that swelling begins in muscle 
tissue and consequently activates free nerve endings, but is ultimately shifted to 
subcutaneous areas.111 Since the MRI cannot satisfactorily distinguish between the two 
compartments, this may help illuminate the differences in time-course between soreness 
and swelling.  Alternate agents (e.g. bradykinin, prostaglandin E2, histamine) released 
upon damage stimulate nerve afferents that transmit pain sensations.114 However, direct 
evidence is lacking that any of these chemicals are responsible for DOMS. 
 Using muscular dystrophy patients, Sibley and Lehninger (1949) were the first to 
measure the serum activity of a muscle enzyme (aldolase in this instance).133 Enzymes 
such as creatine kinase (CK; CK-MM for skeletal muscle), lactate dehydrogenase (LDH-
2 for skeletal muscle), carbonic anhydrase III, aspartate isoenzyme II, and proteins such 
as myoglobin, myosin heavy chain, and troponin have all been used as indirect evidence 
of muscle damage.137 According to the majority of research, alterations in muscle 
proteins found in the bloodstream do not correlate well with changes in muscle function; 
however, this does not imply that muscle proteins are an invalid method for assessing 
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damage.35-37 In addition, there is conflicting evidence to the previous point; Rodenburg et 
al. (1993) showed significant correlations between MVC torque (elbow extension and 
flexion) and serum CK and myoglobin elevations.121  
The use of muscle proteins provokes controversy because serum concentrations 
are a reflection of not only what the muscle is releasing, but what is being cleared from 
the bloodstream.  Additionally, there is considerable (unexplained) intersubject 
variability when using blood proteins, especially CK.37 Nosaka and Clarkson (1996) 
reported a 236 to 25,244 IU/L range in CK; that withstanding, CK activity correlates well 
with the degree of damage determined by MRI.112 Muscle proteins escape the cell either 
from a physical deformation of the membrane or through an increase in membrane 
permeability possibly produced from an inflammatory response.  Differences in 
molecular weight account for some of the conflicting time-courses the proteins display; 
for example, CK is a large protein and therefore cannot enter the circulation through the 
microvascular epithelium, but instead is initially carried through the lymphatic system.110 
 Table 2-1 presents results from 26 studies that used blood markers or DOMS as 
an indicator of skeletal muscle damage.  With protocols involving aerobic exercise, even 
when eccentrically-biased (e.g. downhill running, backwards cycling), the majority of 
studies show peak muscle enzyme levels at approximately 24 hours post-exercise, 
whereas studies involving resistance training result in peaks 2-5 days post-exercise.  The 
exception to this is LDH, which usually peaks within the first few hours post-aerobic 
exercise.  Regardless of the protocol, DOMS usually peaks at either 24 or 48-hours post-
exercise. 
 
Table 2-1 Results from studies using blood markers or DOMS as an indirect measure 
of skeletal muscle damage. 
 
 
Reference n Gender Protocol Test Test time   Post vs. Pre Sig Peak Time 
     (post-exercise) (if given)  and Conc. 
         (IU/L) 
         (if given) 
 
Apple 12 M marathon CK, 24-96 h SD*  24 h 
et al.8        (3322 3398 
         vs. 149 62) 
    CK-MB 24-96 h SD* 
    
    CK-MB  24-48 h SD*  24 h 
    (% of total CK) 
     72-96 h ND 
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Table 2-1 - continued.  
 
Reference n Gender Protocol Test Test time   Post vs. Pre Sig Peak Time 
     (post-exercise) (if given)  and Conc. 
         (IU/L) 
         (if given) 
 
Bratton 15 M uphill run/walk GOT, GPT 5 min ND 
et al.26   3 degree incline ALS, MDH 
    LDH 
 
   5 degree incline GOT, GPT 5 min SD*** 
    MDH 
     
    ALS, LDH  ND  
      
   8 degree incline GOT, GPT 5 min SD*** 
    MDH, LDH 
 
    ALS  ND 
 
   11 degree incline GOT, GPT 5 min SD*** 
    ALS, MDH 
    LDH 
 
Byrnes 11 M downhill CK 6, 18, 42 h SD* (bout 1 42 h (1) 
et al.29 11 F     running    vs. 2) 6-18 h (2) 
   (two bouts separated   
   by 3 weeks) Mb  ND  10 h (1, 2) 
      
    DOMS  SD* (bout 1 42 h (1) 
       vs. 2) 18 h (2) 
 
   Downhill CK 6, 18, 42 h SD** (bout 1 10 h (1, 2)  
       running    vs. 2) 
   (two bouts separated  
   by 6 weeks) Mb  SD* (bout 1 10 h (1, 2) 
       vs. 2) 
    DOMS  SD** (bout 1 42 h (1, 2) 
       vs. 2) 
 
   Downhill CK 6, 18, 42 h ND (bout 1 18 h (1, 2) 
       running    vs. 2) 
   (two bouts separated Mb  ND (bout 1 10 h (1, 2) 
   by 9 weeks)    vs. 2) 
    DOMS  ND (bout 1 42 h (1, 2) 
       vs. 2) 
 
Cannon 15 M backwards CK 48 h SD*  X 
et al.31 6 F     cycling 
     5, 12 d  ND 
 
Clarkson 8 F eccentric elbow CK 1-2 d ND 
et al.39       flexion (70 reps) 
     3-5 d SD** 5 d 
 
      SD** (from 
       24 reps) 
 
    DOMS 1-5 d SD** 48 h 
 
      SD** (from 
       24 reps) 
 
   eccentric elbow CK 1-3 d ND 
       flexion (24 reps)  
     4-5 d SD** 5 d 
 
    DOMS 1-4 d SD** 24-48 h 
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Table 2-1 - continued.  
 
Reference n Gender Protocol Test Test time   Post vs. Pre Sig Peak Time 
     (post-exercise) (if given)  and Conc. 
         (IU/L) 
         (if given) 
   
     5 d ND  
 
Clarkson 10 F eccentric elbow CK 5, 10, 25 h SD** 25 h 
et al.35       flexion 
    DOMS 5, 10, 25 h SD** 25 h 
 
      SD* (from 
       other two 
       groups) 
 
 8 F isometric elbow CK 5, 10, 25 h SD** 10 h 
       flexion 
    DOMS 5, 10, 25 h SD** 25 h 
 
 10 F concentric elbow CK 5, 10, 25 h SD** 10 h 
       flexion 
    DOMS 5, 10, 25 h ND   
 
Coombes 16 M cycle ergometry CK immediately ND 
et al.42 
     1, 2, 3 h ND 
 
     4, 24 h SD*  24 h 
 
     10, 12 d SD* 
 
     14 d ND 
 
    LDH immediately ND 
 
     1 h ND 
 
     2, 3, 4, 24 h SD*  4 h 
 
     10, 12 d SD* 
 
     14 d ND  
  
Crenshaw 8 M eccentric knee DOMS 48 h N/A                range = 5-8 
et al.46       extensions 
 
   concentric knee DOMS 48 h N/A                range = 0-3 
       extensions  
 
Fielding 9 M downhill CK 24 h SD*  X 
et al.56       running     (307  67 vs.  
     Alternate times            82 13) 
         tested but not 
         reported 
 
Fowler 15 M uphill walk/run GOT, MDH 5, 15, 30, 60 min N/A  5 min 
et al.61 11 F  ALS, LDH 
 
    GPT 5, 15, 30, 60 min N/A  5-15 min 
 
Howell 6 M eccentric elbow DOMS 24-96 h SD** 48 h 
et al.83 7 W     flexion 
     5-6 d SD* 
   




Table 2-1 - continued.  
 
Reference n Gender Protocol Test Test time   Post vs. Pre Sig Peak Time 
     (post-exercise) (if given)  and Conc. 
         (IU/L) 
         (if given) 
 
Jones 5 M eccentric elbow CK 1-6 d N/A  given by 
et al.90       flexion         subject 
 
       Subject 1 5-6 d 
 
       Subject 2 6 d 
 
       Subject 3 3 d 
 
       Subject 4 4 d 
 
       Subject 5 5 d 
 
Karamizrak 33 M (trained) 3 repeated Wingate CK "after" SD*** (larger increase in  
et al.92 30 M (untrained)    tests    untrained)   
    LDH, ALS  SD* (larger increase in 
       untrained) 
 
Kirwan 3 M downhill running CK 48 h SD*  (273 73 vs.  
et al.95 3  F             87 25) 
   cycle ergometry CK 48 h ND 
   (at similar intensity) 
 
Mair 22 M eccentric knee CK 24-72 h SD**** 48 h  
et al.99       extensions 
     96 h   SD*** 
 
    MHC 24-96 h SD**** 72 h 
   
    cTnI same time ND 
         course 
 
    DOMS 24 h N/A (7.5 vs. 1) 
        (1-10) 
     48 h N/A (8 vs. 1) X 
 
     72 h  N/A 
 
     96 h N/A (3.5 vs. 1) 
 
Newham 3 M eccentric elbow CK 24 h ND 
et al.105 5 F     flexion 
     2-8 d SD*  5 d 
 
   same (2 weeks CK 1-5 d ND 
   after first test) 
 
   same (4 weeks CK 24-72 h ND 
   after first test) 
 
Newham 3 M step test DOMS 24-48 h N/A  24-48 h 
et al.108 1 F (one leg (of eccentric- 
   continuously     biased leg) 
   contracted 
   eccentrically) 
 
Ohman 15 M marathon CK 1 h SD* 
et al.115 
     24 h SD*** X 
        (1399 348 
         vs. 102 22) 
     96 h SD** 
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Table 2-1 - continued.  
 
Reference n Gender Protocol Test Test time   Post vs. Pre Sig Peak Time 
     (post-exercise) (if given)  and Conc. 
         (IU/L) 
         (if given) 
 
    CK-MB 1 h SD* 
 
    CK-MB 24 h SD*** X 
 
    CK-MB 96 h SD** 
 
    CK-MB 1, 24 h ND 
    (% of total CK) 
     96 h SD** (below pre) 
 
    LDH 1, 24 h SD*** 1 h 
        (1129 110 
           vs. 234 9) 
     96 h SD** 
 
    AST 1 h SD** 
 
     24 h SD*** X 
 
     96 h SD** 
 
    ALT 1 h SD* 
 
     24, 96 h SD*** 96 h 
 
Rodenburg 12 M eccentric knee CK 72 h SD*  (71 vs. 58) 
et al.123       extensions   
    Mb 72 h ND 
 
    DOMS 24 & 72 h N/A 
 
Rodenburg 27 M eccentric knee CK 1 h ND 
et al.121       extensions 
     24-96 h SD*** 96 h 
 
    Mb 1 h SD*** 
 
     24-96 h  SD*** 72 h 
 
    DOMS 1 h SD*** 
  
     24-96 h SD*** 48 h 
 
Saxton 6 M eccentric elbow CK 72 h ND 
et al.128 6 F     flexion 
     5 d SD*  X 
        (2849 852 
           vs. 68 13) 
  
    DOMS 24-96 h SD** 72 h 
 
     5 d SD* 
 
Schwane 7 M downhill running CK 24 h SD** X 
et al.129                    (351%  increase 
                        from baseline) 
     48-72 h ND 
 
    LDH 24-72 h ND  
 




Table 2-1 - continued.  
 
Reference n Gender Protocol Test Test time   Post vs. Pre Sig Peak Time 
     (post-exercise) (if given)  and Conc. 
         (IU/L) 
         (if given) 
 
Siegel 15 M marathon CK-MB immediately N/A 
et al.134      (15-fold increase) 
      
     4 weeks N/A 
      (slightly below pre) 
 
    CK-MB immediately, 4 weeks N/A 
    (% of total CK)  (similar to pre) 
 
Smith 13 M eccentric chest CK 24 h ND  
et al.136       press (one bout) 
     48-144 h SD**** 72 h 
        (2361 340 
           vs. 95 10)  
 
     7-8 d ND   
   
    DOMS 24-96 h SD**** 48 h 
 
     5 - 8 d ND 
 
Stansbie 70 N/A marathon CK immediately N/A 
et al.140      (four-fold increase) 
 
Tiidus N/A M & F isotonic knee CK 5, 8, 24, 48 h ND 
et al.146       extensions 
   (35 % 10RM) LDH 24-48 h ND 
     
    DOMS 24-48 h ND 
 
   isotonic knee CK 5, 8 h SD* 
       extensions 
   (70% 10 RM)  24-48 h SD** 24 h 
   (90% 10 RM)  
    LDH 24 SD* 
 
     48 h SD** X 
 
    DOMS 24-48 h SD*  48 h 
___________________________________________________________________________________________________________ 
Notes:  
# = if a time course is given, tests were performed every 24 hours within period and significance level applies to all time points 
Peak = time of largest measure 
Reps = repetitions 
 
M = male; F = female; N/A = specific data was not provided; ND = no statistical difference; SD = statistically significant difference 
 
CK = creatine kinase; MHC = myosin heavy chain; cTnI = cardiac troponin I; Mb = myoglobin; LDH = lactate dehydrogenase; AST = 
aspartate transaminase; ALT = alanine transaminase; ALS = aldolase; GOT = glutamic oxaloacetic transaminase; GPT = glutamic 
pyruvic transaminase; MDH = malic dehydrogenase 
 
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p <0.0001 
 
Warren et al. (1999) concluded that MVC force/torque is the superior method in 
determining the extent of muscle damage, although the majority of studies cited used 
MVCs as a method of damaging muscle as opposed to assessing damage.160 A MVC 
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torque measure has high reliability (intraclass correlation coefficients   0.85) and is valid 
assuming measurements are always made at the same joint angle.1, 94 The only drawbacks 
to using MVC torque as a determinant of damage is that fatigue-induced reductions are 
hard to distinguish from injury-induced ones.58 In addition, there may be differences in 
motor unit recruitment patterns post-aerobic or resistance exercise.126 Although some 
researchers have used electrical stimulation to try and circumvent this drawback, external 
stimulation does not guarantee superior validity since it does not recruit an entire muscle 
or muscle group.126, 160 Although Warren’s conclusions are focused towards eccentrically-
induced injuries, the benefit of using MVC torque to quantify functional decrements is 
clear. 
Table 2-2 presents results from studies using MVC torque as an indicator of 
skeletal muscle damage.  The only study using an aerobic protocol reports that MVC 
torque recovers to pre-exercise values by 30-minutes post-exercise.108 The remainder of 
the studies, using resistance exercise as the method to damage muscle, demonstrate that 
MVC torque may be lower as compared to pre-exercise values for up to 5 days post-
exercise. 
 




Reference n Gender Protocol Test Test time  Post vs. Pre Torque Sig. 
     (post-exercise) _____________________                                          
 
Clarkson 8 F eccentric elbow isometric 1-5 d (average) -32.10% SD** 
et al.39       flexion (70 reps)     MVC    (from 
        24 reps) 
   eccentric elbow  1-5 d (average) -5.93% 
       flexion (24 reps) 
 
Crenshaw 8 M eccentric knee isometric immediately -20.73% ND  
et al.46       extensions     MVC   
 
   concentric knee  immediately +2.76% ND  
       extensions           
 
Gibala 8 M eccentric elbow isometric immediately -32.23% SD*  
et al.69       flexion     MVC      
     24 h post -35.56% SD* 
 
     48 h post -39.17% SD* 
 
     72 h post -23.06% SD* 
 




Table 2-2 - continued. 
 
Reference n Gender Protocol Test Test time  Post vs. Pre Torque Sig. 
     (post-exercise) _____________________                                          
 
   concentric elbow  immediately -20.86% SD* 
       flexion   
 
     24 h post -9.02 % ND 
 
     48 h post -7.81% ND 
 
     72 h post -5.11% ND 
 
     96 h post -1.75% ND 
 
Howell 6 M eccentric elbow isometric 24 h post -35% SD** 
et al.83 7 W     flexion     MVC 
      
     2-9 d post N/A 
      
     10 d post -30% SD** 
 
Newham 3 M eccentric elbow isometric 24 h post -51% SD* 
et al.105 5 F     flexion     MVC 
 
   same (2 weeks  24 h post -34% SD* 
   after first test) 
 
   same (4 weeks  24 h post -31% SD* 




Newham 3 M step test isometric 2 min post N/A  SD*** 
et al.108 1 F (one leg     MVC 
   continuously (of eccentric- 10 min post N/A  SD*** 
   contracted     biased leg) 
   eccentrically)  30 min post N/A  ND 
 
     1 h post N/A  ND 
   
     5 h post N/A  ND 
 
     24 h post N/A  ND 
 
     48 h post N/A  ND 
 
Rodenburg 27 M eccentric elbow isotonic 1 h post N/A  SD*** 
et al.121       flexion     MVC 
     24 h post N/A  SD*** 
 
     48 h post N/A  SD*** 
 
     72 h post N/A  SD*** 
  
     96 h post N/A  SD*** 
 
Saxton 6 M eccentric elbow isometric immediately -47.71% SD** 
et al.128 6 F     flexion     MVC  
     24 h post -37.18% SD** 
 
     48 h post -35.39% SD** 
 






Table 2-2 - continued. 
 
Reference n Gender Protocol Test Test time  Post vs. Pre Torque Sig. 
     (post-exercise) _____________________                                         
      
     72 h post -25.65% SD** 
 
     4 d post -22.07% SD** 
 
     5 d post -19.48% SD** 
 
___________________________________________________________________________________________________________ 
M = male; F = female;  MVC = maximal voluntary contraction; N/A = specific data was not provided; ND = no statistical difference; 
SD = statistically significant difference; reps = repetitions 
* p < 0.05, ** p < 0.01, *** p < 0.001 
 
BCAA Ingestion and Muscle Damage 
 The attempt to reduce muscle damage through nutritional supplementation is not a 
novel venture.71 However, most of the research has used antioxidants in the attempt to 
attenuate the injury-induced inflammatory response that may cause a “secondary” wave 
of damage.37, 71 Assuming the metabolic hypothesis of muscle damage is valid, nutritional 
supplementation may provide a means to help keep ATP levels stable during prolonged 
exercise.  As previously mentioned, protein catabolism/degradation can result in similar 
responses as mechanical strain-induced injury that were previously discussed.11, 42 
 Several hypotheses as to why BCAA supplementation would help reduce muscle 
damage during aerobic exercise exist.  An elevated BCAA concentration has an increased 
anabolic and decreased catabolic effect regarding muscle proteins (both myofibrillar and 
membrane-bound).28, 32, 148 The anabolic effect of BCAA may be due to changes in 
hormone levels; exogenous BCAA increases testosterone and human growth hormone 
when given before aerobic exercise, as well as elevating the insulin-sensitivity of 
muscle.32, 66 In regards to protein degradation, both the administration of BCAA and 
alpha-ketoisocaproate (KIC) inhibit protein catabolism in vitro.28, 148 Since BCAA 
supplementation increases BCKAD activity, more KIC is available as it is the keto 
analogue of leucine; consequently, muscle protein degradation may be suppressed.  In 
addition, Tipton and Wolfe (1998) proposed a hypothetical model that suggests a 
decrease of AA in the free muscle pool, as would occur during prolonged exercise, might 
act as a signal to promote muscle protein degradation, thereby replenishing the pool.147 
Therefore, keeping the pool high in BCAA through supplementation could help suppress 
the signal for breakdown. 
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 Leucine may have a direct effect on protein metabolism; this stimulatory effect 
has been associated with enhanced activity of eukaryotic initiation factor 4F.6, 7 Since this 
initiation factor is responsible for synthesis, leucine may stimulate synthesis as opposed 
to reduce degradation.6, 68 But, leucine infusion at rest decreases the levels of tyrosine and 
phenylalanine in the muscle.5 It should be noted that all of the data in these studies are 
from rats and that human muscle metabolism may be regulated differently. 
 The research investigating the plausibility of BCAA ingestion reducing exercise-
induced muscle damage during aerobic exercise is scarce.  To date, no study using direct 
measures of muscle damage (biopsy, MRI) exists.  Measuring efflux from the muscle of 
the aromatic AA, tyrosine and phenylalanine, is a method used to estimate the net rate of 
protein degradation, as the muscle does not metabolize these AA.154 Blomstrand et al. 
(1991) reported significant elevations in plasma of both aromatic AA post-marathon race 
as compared to pre-race in a placebo group (tyrosine: 78   14 vs. 64   18; phenylalanine: 
76   7 vs. 64   9  mol/L); these elevations do not exist in a BCAA-supplemented group 
(tyrosine: 69   8 vs. 67   18; phenylalanine: 67   10 vs. 67   12  mol/L).22 The dietary 
contribution of BCAA was not recorded and may have served as a confounding factor.  
There are no changes in plasma aromatic AA concentrations pre- to post-30 km race for 
either the placebo (tyrosine: 99   20 vs. 94   16; phenylalanine: 79   14 vs. 78   12 
 mol/L) or experimental group (tyrosine: 89   15 vs. 78   14; phenylalanine: 76   10 vs. 
69   13  mol/L), indicating that the exercise may have to be of prolonged duration (> 2 
hours) in order to benefit from supplementation.22 Table 2-3 shows the supplement helps 
attenuate the loss of BCAA from the bloodstream in both races. 
 
Table 2-3: Results from Blomstrand, et al. (1991). 
All units  mol/L: 
Plasma Concentrations (30 km Placebo Trial) Pre-exercise  Post-exercise 
Leucine   188   51   134   29*** 
Isoleucine  97   28   65   17*** 
Valine   330   80   245   49***  
(Table 2-3 continues on the following page) 
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Table 2-3 - continued. 
Plasma Concentrations (30 km BCAA Trial)  
  Leucine   170   30   208   73 
  Isoleucine  90   17   94   33 
  Valine   298   47   542   160*** 
Plasma Concentrations (Marathon Placebo) 
  Leucine   150   31   121   15*** 
  Isoleucine  77   19   57   9*** 
  Valine   300   57   250   57*** 
Plasma Concentrations (Marathon BCAA Trial) 
  Leucine   150   40   270   56*** 
  Isoleucine  77   22   150   40*** 
Valine   300   90   830   220*** 
   * p < 0.05, ** p < 0.01, *** p < 0.001 respectively for post- vs. pre-exercise values 
 
Data conflicting with the hypothesis that a long duration (>2 hours) is necessary 
to benefit from BCAA supplementation come from subjects most likely competing in the 
same races.23 After the 30 km race, plasma tyrosine concentrations are significantly lower 
in the BCAA supplemented group post-exercise (78   4.0  mol/L) than pre-exercise (91 
  4.5  mol/L); the same results are found for phenylalanine (69   3.6 vs. 76   2.7 
 mol/L).  Free AA concentrations are also measured in muscle samples from the vastus 
lateralis before and after exercise.  While the supplemented group exhibits no significant 
differences between pre- and post-race levels (75   4.8 vs. 81   4.0  mol/L for tyrosine; 
53   3.5 vs. 61   4.1  mol/L for phenylalanine), the placebo group has significantly 
elevated concentrations of the aromatic AA post-exercise (73   3.1 vs. 90   3.5  mol/L 
for tyrosine; 49   2.4 vs. 65   3.9  mol/L for phenylalanine) indicating muscle 
proteolysis.  The prevention of muscle proteolysis is also seen pre- and post-marathon.23 




Table 2-4 Results from Blomstrand et al. (1992). 
All plasma mol/L; all muscle measurement units  mol/kg dry wt. 
Plasma Concentrations (Placebo Trial)  Pre-exercise  Post-exercise 
Tyrosine   78   5.6   87   3.6* 
Phenylalanine  68   4.0   79   2.4** 
Leucine   163   11   126   4.8*** 
Isoleucine  83   6.2   61   2.3*** 
Valine   291   17   228   10*** 
Plasma Concentrations (BCAA Trial)  
  Tyrosine   82   7.2   81   5.4 
  Phenylalanine  68   4.7   71   2.9 
  Leucine   150   12   173   11 
  Isoleucine  77   6.3   101   8.5** 
  Valine   280   16   420   31*** 
Free AA Concentrations in Muscle (Placebo) 
  Tyrosine   61   5.2   86   6.1** 
  Phenylalanine  56   4.0   74   5.5* 
  Leucine   124   7.0   120   9.5 
  Isoleucine  60   3.2   58   4.9 
  Valine   192   10   191   14 
Free AA Concentrations in Muscle (BCAA) 
  Tyrosine   84   7.9   89   7.3 
  Phenylalanine  64   3.8   72   2.6 
  Leucine   141   3.4   184   15* 
  Isoleucine  69   2.0   101   11* 
Valine   216   6.5   393   53* 
   * p < 0.05, ** p < 0.01, *** p < 0.001 respectively for post- vs. pre-exercise values 
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Clearly, the BCAA supplement helps attenuate the loss of BCAA from the bloodstream 
as well as increasing their presence in the free muscle pool. 
While exercising the knee extensor muscles for 60 minutes on one leg, the plasma 
phenylalanine levels are lower at 30 minutes (38   3 vs. 46   2  mol/L) and 45 minutes 
(37   3 vs. 44   3  mol/L) in a BCAA supplemented trial as opposed to a placebo trial.97 
In addition, the total release of essential AA (minus BCAA) is less in the supplement trial 
(531   70 vs. 924   148  mol/kg).97 
 Blomstrand and Saltin (2001) showed that BCAA intake reduces protein 
degradation after but not during exercise in both glycogen-reduced (via previous 
exercise) musculature and normal-glycogen conditions.25 Results for the aromatic amino 
acids are presented in Table 2-5. 
 
Table 2-5 Results from Blomstrand and Saltin (2001). 
All units  mol/kg dry wt. 
Low glycogen leg: 
Placebo Trial Rest  Post-exercise .5 h post  1 h post  2 h post 
Tyrosine  192   15  262   20* 254   18* 229   27  199   20 
Phenylalanine 181   14  254   17* 239   13  215   20  193   18  
BCAA Trial 
Tyrosine  181   13  246   13* 225   16* 167   19^ 128   17*^ 
Phenylalanine 176   4.7  234   12* 213   16* 151   17^ 129   18*^ 
Normal glycogen leg: 
Placebo Trial Rest  Post-exercise .5 h post  1 h post  2 h post 
Tyrosine  211   10  257   17* 260   22* 210   15  193   21 
Phenylalanine 202   13  271   16* 260   25  204   14  202   21 
BCAA Trial 
Tyrosine  199   11  256   17* 220   18  181   18^ 135   16*^ 
Phenylalanine 189   15  245   19* 217   25  175   18^ 139   18*^ 
     * p < 0.05 vs. resting value; ^ p < 0.05 for BCAA vs. placebo 
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These results indicate that BCAA supplementation provides an ultimately anabolic effect 
post-exercise.  Not only do the aromatic AA return to basal levels faster with 
supplementation, they were released in smaller rates.  These results are similar to Rohde 
et al. (1997) who found that BCAA supplementation before exercise reduced the release 
of AA after eccentric exercise.124 
 However, there is evidence to the contrary.  During exhaustive cycling exercise, 
there are no differences in plasma concentrations of tyrosine and phenylalanine reported 
between a BCAA supplemented trial and a placebo trial at 20, 40, 60, and 80 minutes of 
exercise, as well as 5 minutes post-exercise.20 In glycogen-depleted subjects, Blomstrand 
et al. (1995) reported that while exhaustive aerobic exercise (80 minutes) elevates plasma 
concentrations of both tyrosine and phenylalanine, neither CHO nor CHO+BCAA helped 
attenuate protein degradation.18 Unfortunately no specific data are available. 
 Only one study examines the effect of BCAA supplementation on standard blood 
indicators of muscle damage.42 Coombes and McNaughton (2000) supplemented 16 male 
subjects for 14 days with 6 grams of BCAA twice a day, with an additional 20 grams 
given before and after the 2-hour cycle ergometry trial (70% VO2 max).  Subjects, 
whether assigned to the placebo group or supplemented group, were required to consume 
at least 0.64 g/kg/day of BCAA (a value obtained from the high recommendation of 1.6 
g/kg/day protein and a suggestion that BCAA account for 40% of total protein intake).3 
Although specific values were not reported, serum CK values for the supplemented group 
are lower than the control group at 4 hours, 24 hours, 3 days, and 5 days post-exercise.  
Serum LDH values followed the same pattern as they are reduced in the supplemented 
group (relative to the control group) at 2 hours, 3 hours, 4 hours, 1 day, 3 days, and 5 
days post-exercise.  Serum CK activity usually peaks 24-48 hours post-aerobic exercise 
while serum LDH will typically peak within 8 hours post-exercise; these results are 
typical with serum CK peaking at 24 hours and LDH peaking at 4 hours in both groups.91 
 There are two major flaws in this experimental design; different subjects are used 
for the placebo trial and the supplemented trial.  The large inter-subject variability in 
blood responses (particularly CK) has been documented; even though statistical outliers 
may not have been identified, it cannot be confirmed whether subjects in different groups 
 28
would have had similar blood protein responses to exercise as they were only matched by 
VO2 max.37 More importantly, the supplemented group is given BCAA not only the 14 
days prior to the exercise trial, but immediately before and after.  Therefore, it could be 
speculated that providing energy prior to and after the exercise trial is what helped 
attenuate damage.  BCAA are not the only product that could be rationalized to prevent 
damage; providing CHO prior to exercise reduces the need to use amino acids for energy 
and, therefore, attenuate protein breakdown and consequently, muscle damage.  CHO 
ingestion could also provide an insulin response that in turn reduces protein breakdown. 
 A recent study by Saunders et al. (2004) also indicates that amino acid 
supplementation may help reduce muscle damage (note: whole protein was supplemented 
as opposed to just BCAA).127 During two cycling trials separated by 12-15 hours, 15 
male subjects were given either a CHO or a non-isocaloric CHO+protein beverage (the 
CHO+protein beverage provided approximately 46 kilocalories more energy than the 
CHO beverage).  There is no mention of dietary analysis to ensure similar nutrition prior 
to the trials.  Serum CK values are significantly lower post-ride 1 after the CHO+protein 
trial as opposed to the CHO only trial (no specific data are given).  Also, subjects ride 
29% and 40% longer during rides 1 and 2, respectively, when consuming the 
CHO+protein beverage. 
 As previously mentioned, the beverages are not matched by calories but rather by 
CHO content.  During ride 1, cyclists ingested 139 kcals more in the CHO+protein trial 
although this is partially attributable to the CHO+protein exercising for a longer duration.  
Granted, since CHO content above 6-10% does not aid performance the addition of 
protein to a beverage could help to increase the caloric content without manipulating the 
fluid volume.40 However, due to the caloric difference, it cannot be concluded that the 
performance benefit or attenuation of muscle damage was a result of protein ingestion or 
simply additional caloric intake.  In addition, it is more difficult to delineate mechanisms 
when whole protein is used as any individual amino acid could theoretically have an 






 There is sufficient evidence to suggest that BCAA ingestion during prolonged 
endurance exercise may attenuate skeletal muscle damage.18, 22, 23, 25, 42, 77, 97, 127 However, 
the published studies that have used common indirect methods of determining muscle 
damage all contain significant design flaws thus making it difficult to determine whether 
the reduced damage was due to BCAA intake or other confounding factors.42, 127 There is 
currently no published research examining the effects of BCAA supplementation on 
muscle damage as compared to an isocaloric non-protein supplement.  The published 
studies have only used blood markers as a measure of damage as well.42, 127 Alternate 
methods of determining damage need to be employed due to the drawbacks of using 
blood markers as previously outlined.  Additionally, the attempt to blunt central fatigue 
with BCAA ingestion has resulted in mixed conclusions.18, 19, 21, 22, 78, 98, 141, 150, 153 Further 
























Untrained, college-aged men were used for this study.  Initial exclusionary criteria 
included: females, in order to avoid the influence that gender may have upon muscle 
damage;37 current smokers or those who have smoked regularly within the past year to 
minimize obstacles in the ability to perform prolonged aerobic exercise; individuals who 
have engaged in regular aerobic or anaerobic training within the past year; and those who 
were taking or had taken any dietary supplement (with the exception of multivitamins or 
minerals) within the past six months. 
 In order to determine subject number that gives a power of .80 at a two-tailed 
alpha level of 0.05, the equation n = 2( /d)2 in which n = subject number,   = expected t 
value, and d = effect size was utilized.  For the proposed power and alpha level, a   of 2.8 
was expected.41  
The first priority was to guarantee that a significant difference would be found 
between pre- and post-measurements of damage, and secondly to determine if any 
differences could be detected between the post-measurements between trials.  
Unfortunately, studies that have measured these enzymes with protocols similar to the 
present proposed one did not report specific data but instead only presented data in graph 
form.26, 61, 129  
Ohman et al. (1982) measured both CK and LDH before and after a marathon in 
15 trained men.115 Using the equation, d = ( 1 -  2)/ , in which   is the larger standard 
deviation of the two means (thus giving the most conservative effect size), Ohman et al. 
reported a peak effect size of 3.73 [(1399 - 102)/348] for CK (at 24-hours post-exercise), 
and 8.14 [(1129 - 234)/110] for LDH (at 1-hour post-exercise).115 Although a marathon 
race would be performed at a higher intensity and a longer duration than the protocol 
proposed for the present study, well-trained subjects were used which would have greatly 
reduced the extent of damage observed (and thus lowered the effect size between pre- and 
post-measurements); additionally, it involves a non-eccentrically biased exercise (which 
does not produce enzyme levels in the blood as elevated as eccentrically biased).84, 113, 145  
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Fielding et al. reported an effect size of 3.34 [(307.2 - 81.9)/67.4] for CK (at 24-
hours post-exercise) as a result of damage incurred during a 45-minute downhill run at 
70% heart rate maximum (perhaps a more appropriate comparison to the proposed 
study).56 Therefore, with effect sizes in excess of 3.0, finding significance between pre- 
and post-measurements of muscle damage (at least in regards to a placebo trial) was not 
of major concern. 
It was difficult to estimate an effect size in regards to detecting differences in the 
primary dependent measures (a placebo group, a CHO-supplemented group, and a 
BCAA-supplemented group), since the only two studies that examine the present topic 
did not report specific data.  Coombes et al. found significant differences between a 
BCAA group and a placebo group with 16 subjects (eight per group); however, this study 
does not utilize a powerful repeated-measure design that would have greatly increased 
power and thus could have reduced the necessary subject number in each group (and 
reduced the number of total subjects by at least half).42 Saunders et al. reported that 15 
subjects were necessary to achieve a power of .80 based upon pilot data and an estimated 
effect size of 1.0.  However, the results indicate a much larger effect size (> 2.0) and 
therefore (as suggested in the article) the subject number exceeds the necessary sample 
size.127 
Therefore, even if a conservative estimate of 1.5 is used for an effect size, the 
required subject number was 6.97 [(2.8/1.5)2 x 2].  This number was raised to nine 
subjects since three trials were necessary for each participant and thus no trial 
(supplemented or placebo) was given an advantage in regards to any repeated bout 
effects. 
 
Subject Screening and Preliminary Procedures 
 On the first visit to the laboratory, each volunteer completed a medical history 
form that revealed contraindications to exercise.  Provided there were no 
contraindications to exercise, each volunteer signed an informed consent approved by the 
Florida State University Institutional Review Board for Research Involving Human 
Subjects after being informed of the nature of the study and the risks involved.  At this 
time, subjects were given instructions regarding the dietary and physical activity 
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restrictions of the study.  Although it was assumed that untrained participants would not 
engage in any exercise with exception of the experimental trials, any strenuous physical 
activity was discouraged throughout the course of the experiment. 
 Following 10 minutes of seated rest, resting blood pressure (BP) was assessed 
manually at the brachial artery.  A resting BP at or above 140/90 mmHg was considered 
exclusionary criteria.  Height (to the nearest 0.1 cm) and weight (to the nearest 0.5 kg) 
were measured, as well as body composition via the Jackson and Pollock (1985) three-
site formula (chest, abdomen, thigh) and Siri equation (1956) for estimating body fat 
percentage.87, 135 A continuous, graded exercise test (Astrand Maximal Cycle Protocol) on 
a Monark cycle ergometer was used to assess maximal oxygen consumption.12 
 All volunteers received written and verbal instructions by the primary investigator 
on how to follow the dietary requirements for this study.  Subjects kept detailed records 
of dietary intake for three days prior to (and the day of) each exercise session, and were 
asked to avoid eating for four hours prior to each exercise trial.  Subjects were 
encouraged to maintain the same dietary patterns for the three days prior to each trial 
(dietary choices on the day of exercise were not permitted to change); once handed into 
the primary investigator, dietary records were copied and returned to the subject to aid 
this endeavor.  Each participant received an exchange list of foods (American Dietetic 
Association & American Diabetic Association Food Exchange List) to help increase 
adherence to the restrictions by allowing alternative dietary choices during the three day 
period.  Dietary information was analyzed using a commercially available dietary 
analysis software package (Nutritionist Five, Version 2.0, First DataBank, Inc., San 
Bruno, CA).  Mean energy intake (kilocalories/day), mean CHO intake (g/day), mean 
protein intake (g/day), mean fat intake (g/day), mean vitamin C intake (mg/day), and 
mean vitamin E intake (IU/day) were computed to verify that these components did not 
significantly differ between trials.  These nutritional variables were chosen for their 
potential effects on performance and/or muscular damage.71 No specific action was taken 
if a subject did not follow the same dietary patterns as he did before a previous exercise 
bout with the exception of the day of exercise (in which the action would be to not allow 
the exercise trial to take place).  However, if statistical analyses revealed a significant 
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 There were three treatment phases for this study.  Each phase consisted of four 
visits to the laboratory, and eight weeks separated the initial day of each phase to allow 
for full muscle recovery from damage and reduce the effects of the repeated bout effect.8, 
31, 42, 83, 120, 129 Weight and resting BP were taken prior to every treatment.  Approximately 
15 minutes before an aerobic exercise trial commenced, maximal voluntary leg flexion 
and extension torque were assessed through isokinetic work on a BiodexTM dynamometer.  
Prior to this test and following 15 minutes of seated rest, a resting blood sample was 
drawn from an antecubital vein.  Following a warm-up (which the dynamometer controls 
automatically), subjects performed three sets of three repetitions of leg flexion and 
extension at 180 /second.  One minute of rest was given in between each set, and the 
peak value for flexion and extension was recorded.   
The subject was given a five-minute warm-up on a Monark cycle ergometer at 50 
revolutions per minute (RPM) and a resistance of 1 kp.  Following the warm-up, the 
resistance (as determined by the preliminary procedure) was increased to a workload 
eliciting an intensity of 55% VO2 max.  Steady-state exercise continued for 90 minutes, 
after which subjects completed a 15-minute time-trial wherein they covered as much 
distance as possible.  The decision to set a duration for the time-trial as opposed to a 
distance (in which time to completion would be recorded instead) was based upon the 
premise that untrained subjects, due to lack of cycling experience, were able to more 
appropriately pace themselves with a duration in mind, whereas a given distance to these 
subjects may have been a meaningless notion.  Even though the trials are randomized, 
this helped avoid a large learning curve from one trial to the next.  Expired air was 
monitored through open-circuit indirect spirometry; VO2, ventilation, heart rate (HR), 
respiratory exchange ratio (RER), and rate of perceived exertion (RPE) were assessed at 
15-minute intervals during the steady-state ride.  
 There were three treatment phases that differ in the content of beverage consumed 
during the steady-state ride.  Beverages were administered five minutes prior to the 
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initiation of exercise, as well as at the 60-minute mark.  A placebo beverage was non-
caloric and contained only water, lemon flavor, salts, and artificial sweetner.  A CHO-
containing beverage (Gatorade, Inc., Chicago, IL) was used, as well as an isocaloric 
BCAA-containing beverage ("Ni"- Musashi, Notting Hill, Australia).  One serving (2.5 g) 
of the BCAA beverage contained 480 mg isoleucine, 1.22 g leucine, and 730 mg valine 
(10 calories).  The beverages were indistinguishable in taste (with the addition of 
artificial sweetner and lemon flavor) and their appearance was hidden.  Subjects were not 
made aware of which beverage they were consuming in order to prevent any potential 
placebo effects on performance.  The total amount of energy given to subjects over the 
two time-points was 200 calories (50 grams of BCAA or 50 grams of CHO).  This 
amount was chosen as it is consistent with what prior research has been shown to be an 
effective dose to reduce muscle damage.42, 127 
 Post-exercise maximal voluntary leg flexion and extension torque was measured 
10 minutes after the completion of the time-trial, as well as 4-hours, 24-hours, and 48-
hours post-exercise.  In addition to the pre-exercise sample, a resting blood sample was 
taken immediately post-exercise as well as 4-hours, 24-hours, and 48-hours post-exercise; 
blood sampling was not carried out for a longer period since it was expected that LDH 
would peak approximately four hours post-exercise and CK would peak approximately 
24 hours post-exercise after non-eccentrically biased aerobic exercise.91 Muscle soreness 
(measured on a 1-10 point scale) was self-reported on the same time course as the blood 
sampling. 
 Plasma glucose and BCAA concentrations were also assessed from the pre- and 
immediately post-exercise samples. 
 
Instrumentation 
Body weight was measured on a Seca scale (Model 707, Seca Corporation, 
Columbia, MD) to the nearest 0.5 kg.  Subjects were weighed in their workout clothes 
with the exception of shoes.  Height was measured on a stadiometer (Medart, St. Louis, 
MO) to the nearest 0.1 cm; likewise, this measurement was made without footwear.  
Body fat was assessed using the Jackson and Pollock (1985) three-site formula (chest, 
abdomen, thigh) and Siri equation (1956) for estimating body fat percentage.87, 135 
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Measurements were performed using procedures outlined in the ACSM's Guidelines for 
Exercise Testing and Prescription (2000).2 Lange skinfold calipers (Cambridge Scientific 
Industries, Inc., Cambridge, MD) were used for this procedure; triplicate measures were 
made at each site unless they are not within 1-2 mm wherein an additional measurement 
was made and averaged with the first three. 
Resting BP was assessed manually using a stethoscope and a sphygmomanometer 
(General Medical Corporation, Richmond, VA).  HR was measured throughout the 
exercise trial with a Polar heart rate monitor (Polar CIC Inc., Port Washington, NY).  
RPE was measured using Borg's 6- to 20-point scale which has been determined to be a 
valid and reliable (subjective) measure of intensity.2 
Oxygen utilization, carbon dioxide production, and ventilatory measurements 
were made at the aforementioned durations of each exercise trial as well as during the 
determination of VO2 max.  Expired air was delivered to the metabolic system through a 
mouthpiece (Vacumed, Ventura, CA) and multi-directional non-rebreathing tube (Hans 
Rudolph, Inc., Kansas City, MO).  The metabolic cart (Truemax 2400 Metabolic 
Measurement System, Consentius Technologies, Sandy, UT) used to make these 
measurements was calibrated before each trial.  A 3-Liter syringe (Hans Rudolph, Inc., 
Kanasa City, MO) was used for flow calibration, and gas calibration was performed using 
a gas mixture with known concentrations of oxygen and carbon dioxide (Scott Medical 
Products, Plumsteadville, PA).  As the metabolic system adjusted for environmental 
factors, ambient temperature, humidity, and barometric pressure were recorded using a 
climate monitor (Perception IITM, Davis Instruments, Hayword, CA) and entered 
manually into the system.  All exercise is performed on a Monark Ergomedic 828E cycle 
ergometer (Monark Exercise AB, Vansbro, Sweden) that was calibrated before each 
exercise trial according to the manufacturer's specifications.  This model also computed 
RPM and distance covered (km). 
Maximal voluntary leg flexion and extension contraction torque measurements 
were made isokinetically on a Biodex dynamometer (BiodexTM, Shirley, NY).  This 
system automatically calibrated prior to each trial.  Rates of perceived soreness were self-
reported on a 1-10 scale (1: no soreness; 10: maximal soreness).160 
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Blood Sampling, Storage, and Analysis 
 Blood samples were taken from an antecubital vein after 15 minutes of seated rest 
and collected in Vacutainer blood collection tubes (Becton Dickinson, Franklin Lakes, 
NJ).  Vacutainer tubes were used for serum collection (CK, LDH); tubes containing 
sodium fluoride and potassium oxalate were used for plasma glucose collection; tubes 
with sodium heparin and lithium heparin were used for plasma BCAA collection; and 
tubes containing K2EDTA were used for hemoglobin and hematocrit measurements.  
Universal blood handling precautions were followed.  Whole blood samples were 
allowed to coagulate at room temperature before being centrifuged (Sorvall RT7, DuPont 
Sorvall Products, Newton, CT) for 20 minutes at 3,000 g in order to fully separate the 
serum/plasma and red blood cells.  Serum and plasma were transferred into 2.0 mL 
microcentrifuge tubes (National Scientific Supply Co., Inc., Claremont, CA) and stored at 
negative 20 degrees Celsius until analysis was performed. 
 Total CK, LDH, and glucose were determined by manual assay (Stanbio 
Laboratory, Boerne, TX).  BCAA concentrations were measured by reversed-phase high 
performance liquid chromatography according to Pfeifer et al. (1983), using 5% 
trichloroacetic acid as the deproteinizing agent.117 All variables were adjusted for plasma 
volume shifts using the formula devised by Dill and Costill (1974).50 Both hemoglobin 
and hematocrit were needed for this formula.  Hemoglobin was determined by manual 
assay (Pointe Scientific, Inc., Lincoln Park, MI) performed in triplicate using whole 
blood. 
Using a microcapillary method, hematocrit was assessed in triplicate with whole 
blood samples.  An IEC Micro MB centrifuge (International Equipment Company, 
Needham Heights, MA) spun heparinized micro-hematocrit capillary tubes (Fisher 
Scientific, Pittsburgh, PA) that contained the whole blood sample for 7 minutes.  Percent 
hematocrit was assessed with use of a circular micro-capillary tube reader (International 
Equipment company, Needham Heights, MA).  Both hematocrit and hemoglobin were 





Study Design and Statistical Analysis 
The study followed a 3 x 5 within-subjects design with repeated measures in 
regards to enzyme measurements, MVC torque, and muscle soreness data.  Blood glucose 
and BCAA concentrations were compared with a 3 x 2 design.  However, within-group 
differences were also examined in regards to these variables.  A 3 x 7 design was 
employed for performance data (VO2, ventilation, HR, RER, RPE).  An ANOVA with 
repeated measures was used to analyze the variance of experimental treatments.  Dietary 
information and time trial performance were assessed using a one-way ANOVA.  Within-
group differences for glucose and BCAA concentrations were analyzed with a paired 
sample t-test.  A Tukey HSD post-hoc test was used to determine significant differences 
between means.  Mauchly's Test of Sphericity was used to prove homogeneity of 

























Nine healthy, untrained males participated in this study.  The average subject age 
was 21.56   3.21 years, while average height and weight were 178.36   6.42 cm and 
84.17   17.03 kg, respectively (average BMI = 26.30   4.27).  Subjects had a mean body 
fat percentage of 19.63   6.81% as determined by the Siri equation, and the average 
maximal oxygen uptake was 36.26   2.23 ml/kg/min (3.03   .46 L/min).135 Subject 
characteristics are presented in Table 4-1. 
 
Table 4-1 Mean Subject Characteristics  
Characteristic Age  Height Weight BMI Body Fat VO2 VO2 
 (years) (cm) (kg)  (%) (ml/kg/min) (L/min) 
        
Mean 21.56 178.36 84.17 26.3 19.63 36.26 3.03 
± SD 3.2 6.42 17.03 4.27 6.81 2.23 0.46 
 
Subjects were randomly assigned to one of three treatment orders; three subjects were 
placed in each order.  The treatment orders can be viewed in Table 4-2.  The mean time 
between the first and second trial was 57.89   1.69 days, whereas the mean time between 
the second and third trial was 57.44   1.68 days. 
 
Table 4-2 Treatment Order 
n Trial 1 Trial 2 Trial 3 
    
3 CHO PLAC BCAA 
3 BCAA CHO PLAC 
3 PLAC BCAA CHO 
 






 Subjects recorded their diets for 3 days prior to all exercise trials.  After the first 
exercise bout, they were provided copies of their dietary recalls in order to encourage 
adherence to similar dietary regimes.  Analyses of variance (ANOVA) with repeated 
measures showed that mean energy intake (kilocalories/day), mean carbohydrate intake 
(g/day), mean protein intake (g/day), mean fat intake (g/day), mean vitamin C intake 
(mg/day), and mean vitamin E intake (IU/day) did not differ between trials (p > 0.05).  
As the pre-exercise diets were not significantly different between trials, no dietary factors 
needed to be used as a covariate.  Dietary intake data are presented in Table 4-3. 
 
Table 4-3 Mean Dietary Intake 
   TRIALS  
Day Nutrient CHO BCAA PLAC 
     
1 Energy (kcal) 1955.6 1814.6 1817.4 
 ± SD 639.5 756 610.2 
 CHO (g) 254.3 239.4 214.9 
 ± SD 138 147.6 135.7 
 Protein (g) 68 57.7 65.4 
 ± SD 21 15.7 26.6 
 Fat (g) 53.9 54.8 55.3 
 ± SD 25.2 18.2 26.5 
 Vitamin C (mg) 49.1 28.1 45.4 
 ± SD 53.3 39 53.5 
 Vitamin E (IU) 13.3 13.4 13.5 
  13.1 13.2 12.9 
     
2 Energy (kcal) 2111.3 1814.6 1711.9 
 ± SD 884.3 756 852.6 
 CHO (g) 257.4 239.9 228.2 
 ± SD 145.1 154.7 157.3 
 Protein (g) 77 72 65.4 
 ± SD 37.6 40.4 26.6 
 Fat (g) 69.8 60.7 54.1 
 ± SD 28.6 28.9 25.7 
 Vitamin C (mg) 55.8 55.1 52.2 
 ± SD 46.6 49.7 48.1 
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Table 4-3 - continued. 
 Vitamin E (IU) 14.3 14.2 13.6 
  13.1 12.9 13.1 
     
3 Energy (kcal) 1822.5 1721.6 1714.9 
 ± SD 802.7 768.8 814.4 
 CHO (g) 260.7 246.5 252 
 ± SD 165.8 164.6 170.1 
 Protein (g) 54.4 48.5 60.3 
 ± SD 28 21.8 32.3 
 Fat (g) 44.5 46.3 42.1 
 ± SD 32.8 28.6 25.3 
 Vitamin C (mg) 38.5 50.6 47.7 
 ± SD 39.7 57 41.6 
 Vitamin E (IU) 12.5 12.9 13.2 
 ± SD 13 13 13 
 
During the experimental trials, subjects received either 200 kilocalories of energy from 
the CHO supplement, 200 kilocalories from the BCAA supplement, or <5 calories from 
the Placebo beverage.  Beverages were administered 5 minutes prior to the exercise bout, 
and at the 60-minute mark.  The beverages were similar in taste, and each serving (i.e. 
100 kcals for the CHO or BCAA beverage) was 40 fluid ounces.  The color of the 
beverages was hidden from the subjects. 
 
Blood Markers 
 All results from blood data have been adjusted for plasma volume shifts.  
Hemoglobin, hematocrit, and plasma volume changes are presented in Table 4-4.  
 
Table 4-4 Mean Hemoglobin (g/dL), Hematocrit (%), and Plasma Volume Shifts 
Group Pre Post Post-4 Post-24 Post-48 
      
Hemoglobin      
CHO 15.75 16.39 16.22 16.21 15.98 
± SD 1.3 1.39 1.34 1.25 1.07 
BCAA 15.41 15.92 15.11 15.36 15.53 
± SD 1.43 1.34 1.73 1.36 1.3 
PLAC 15.52 15.88 15.41 15.45 15.3 
± SD 1.56 1.8 1.68 1.65 1.55 
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Table 4-4 - continued. 
Hematocrit      
CHO 43.89 46.62 44.53 44.53 44.07 
± SD 2.4 2.21 2.57 1.85 1.81 
BCAA 45.83 47.67 45.3 45.37 45.65 
± SD 2.58 1.94 3.05 2.22 2.41 
PLAC 44.94 46.68 45.06 44.65 44 
± SD 1.82 2.13 2.72 1.94 1.61 
% Plasma Volume Decrease (relative to Pre value)   
CHO / 2.33 -1.43 -1.37 -0.99 
± SD / 2.12 2.31 1.5 2.54 
BCAA / 0.76 0.87 -0.73 -1.25 
± SD / 1.62 1.77 2.4 1.98 
PLAC / 1.72 0.96 -0.15 -0.75 
± SD / 2.48 2.45 2.49 1.71 
 
Pre = pre-exercise; Post = post-exercise; post-4 = post-4 hours; post-24 = post-24 hours; post-48 = post-48 hours 
 
A Log10 transformation was used in order to reduce the variability within the trials for 
CK data.  The coefficient of variation for CK assays was approximately 4.5%.  ANOVA 
with repeated measures revealed a significant main effect for condition, time, and the 
condition x time interaction (p< 0.05).  Significant differences in serum CK were found 
between the BCAA and Placebo trials at 4, 24, and 48-hour time points; the CK levels in 
the BCAA trial were also reduced as compared to the CHO trial at 24-hours post-exercise 
(p < 0.05).  The CK response was attenuated in the CHO trial as compared to the Placebo 
trial at 24 and 48-hour (p < 0.05).  In all the trials, CK levels had not returned to pre-
exercise levels by 48 hours (p < 0.05), and peaked at 24-hours post-exercise.  The 
Placebo trial was the only to show a significantly elevated CK response immediately 
post-exercise (p < 0.05).  These results are presented in Table D-1 and Figure 4-1. 
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 Figure 4-1 Mean Creatine Kinase Levels 
*
 Significantly greater (p < 0.05) than the BCAA or CHO trial; 
#
 Significantly greater (p < 0.05) than the BCAA trial 
 
Repeated measures ANOVA revealed a significant main effect for condition, time, and 
the condition x time interaction for LDH (p < 0.05).  A significant difference was found 
between the BCAA and Placebo trials at 4-hours post-exercise (p < 0.05).  The BCAA 
trial was the only trial that remained significantly higher than its pre-exercise value at 24-
hours post-exercise (p < 0.05), but had returned to pre-exercise levels by 48 hours (p > 
0.05).  In each trial, LDH values peaked at 4-hours post-exercise.  These results are 
presented in Table D-2 and Figure 4-2.  The coefficient of variation for LDH assays was 
approximately 2.5%. 
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 Figure 4-2 Mean Lactate Dehydrogenase Levels 
*
 Significantly greater (p < 0.05) than the BCAA trial 
 
Maximal Voluntary Leg Flexion/Extension Torque 
There were no significant main effects for the condition or the condition x time 
interaction in regards to MVC leg extension torque (p > 0.05).  However, there was a 
significant main effect for time (p < 0.05).  In all trials, MVC torque significantly 
decreased from pre- to post-exercise, and did not return to pre-exercise values by 48-































 Figure 4-3 Mean Maximal Leg Extension Torque 
*
 All points significantly lower (p < 0.05) than the pre-exercise value 
 
There was a significant main effect for time and a significant condition x time interaction 
in regards to leg flexion (p < 0.05).  Leg flexion torque in the BCAA trial was 
significantly greater (p < 0.05) than both the CHO and Placebo trials at 48-hours post-
exercise.  Each trial resulted in significantly decreased torque from pre- to post-exercise, 
and remained below pre-exercise values for at least 24-hours (p < 0.05); only the BCAA 
trial had returned to pre-exercise values by 48-hours post-exercise (p > 0.05).  These 































 Figure 4-4 Mean Maximal Leg Flexion Torque 
*
 All points significantly lower (p < 0.05) than the pre-exercise value;
 #
 Significantly greater (p < 0.05) than the CHO and 
PLAC trials 
 
Ratings of Perceived Soreness 
Repeated measures ANOVA showed significant main effects for condition, time, 
and the condition x time interaction (p < 0.05) in regards to ratings of perceived soreness.  
The rating of perceived soreness at 24-hours post-exercise was lower in the BCAA trial 
as compared to the CHO and Placebo trials (p < 0.05).  This time-point also represented 
the maximal soreness rating in each trial.  The CHO and Placebo trials' ratings of 
perceived soreness at 24-hours post-exercise were greater than pre-exercise values (p < 
0.05), but had returned to pre-exercise values by 48-hours post-exercise (p > 0.05).  







































 Figure 4-5 Mean Rate of Perceived Soreness 
*
 Significantly greater (p < 0.05) than the BCAA trial; 
#
 Significantly greater (p < 0.05) than pre-exercise values 
 
Time Trial Performance 
There was a significant condition main effect for time trial performance (p < 
0.05).  Post-hoc tests revealed that the cyclists in the CHO trial covered a greater cycling 
distance (4.6   0.6 km) than the Placebo trial (3.9   0.4 km) during the 15-minute loaded 
time-trial (p < 0.05).  The mean distance of the BCAA trial was 4.4   0.5 km which was 
not significantly different from either the CHO or Placebo trials (p > 0.05).  Time trial 
data are represented in Figure 4-6. 
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 Figure 4-6 Mean Time Trial Performance 
 
*
 Significantly greater (p < 0.05) than the PLAC trial 
 
Ratings of Perceived Exertion (RPE) 
Repeated measures ANOVA revealed a significant main effect for time and the 
condition x time interaction for RPE (p < 0.05).  BCAA supplementation lowered RPE at 
75 and 90 minutes (15.22   2.05 and 15.11   2.03, respectively) as compared to the 
Placebo trial (17.11   1.36 and 18.00   1.00, respectively) (p < 0.05).  Results can be 
seen in Figure 4-7. 
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 Figure 4-7 Mean Rating of Perceived Exertion 
*




Measures of aerobic metabolism were taken every 15 minutes during the steady-
state ride.  Repeated measures ANOVA showed no significant main effects for condition, 
time, or the condition x time interaction for VO2 or Ventilation (p > 0.05).  These data 
can be viewed in Table 4-10 and Table 4-11, respectively. 
 
Table 4-5 Mean VO2 (L/min) 
Trial 0:00 0:15 0:30 0:45 1:00 1:15 1:30 
        
CHO 1.68 1.87 1.82 1.79 1.81 1.8 1.79 
± SD 0.22 0.28 0.27 0.36 0.29 0.35 0.38 
        
BCAA 1.6 1.83 1.78 1.73 1.74 1.73 1.77 
± SD 0.18 0.29 0.26 0.28 0.34 0.36 0.38 
        
PLAC 1.66 1.82 1.86 1.72 1.76 1.71 1.72 




Table 4-6 Mean Ventilation (L/min) 
Trial 0:00 0:15 0:30 0:45 1:00 1:15 1:30 
        
CHO 34.05 43.57 42.56 40.59 39.55 39.55 38.62 
± SD 6.25 7.13 5.01 6.72 6.62 6.62 5.81 
        
BCAA 33.36 42.16 40.33 39 40.27 38.2 39.37 
± SD 5.57 7.08 7.32 7.94 9.64 8.93 9.91 
        
PLAC 35.38 43.2 42.25 39.23 40.83 38.9 38.9 
± SD 9.91 9.77 8.31 9.2 10.78 9.4 11.01 
 
There was a significant main effect for time in regards to HR (p < 0.05), but there 
was no main effect for condition or the condition x time interaction.  In all trials, HR 
values taken at 15-minute mark and beyond during exercise were greater than the HR at 
the initiation of exercise (p < 0.05).  HR data can be viewed in Table 4-12. 
 
Table 4-7 Mean Heart Rate (beats/min) 
Trial 0:00 0:15 0:30 0:45 1:00 1:15 1:30 
        
CHO 127.22 151.89 156.67 153.78 155.56 155.11 158.33 
± SD 10.85 15.64 17.15 16.51 14.19 12.67 13.33 
        
BCAA 122.78 146.11 152.78 151.11 151 158.22 157 
± SD 11.78 9.51 11.36 14.24 10.91 8.29 7.05 
        
PLAC 127.22 145.44 152.89 152.33 151.78 155 155.78 
± SD 15.39 15.17 15.64 18.17 15.29 9.21 11.29 
 
There were significant main effects for condition and time in regards to RER (p < 
0.05), but no significant effect for the condition x time interaction.  The last four RER 
measurements (0:45, 1:00, 1:15, and 1:30) taken during the CHO and BCAA trials were 
significantly lower than pre-exercise values, whereas only the last two measurements in 
the Placebo trial were significantly lower than pre-exercise values (p < 0.05).  These data 





Table 4-8 Mean RER Values 
Trial 0:00 0:15 0:30 0:45 1:00 1:15 1:30 
        
CHO 0.99 0.99 0.97 0.93* 0.93* 0.90* 0.92* 
± SD 0.07 0.05 0.04 0.06 0.05 0.07 0.09 
        
BCAA 0.97 0.96 0.94 0.90* 0.88* 0.88* 0.88* 
± SD 0.04 0.06 0.03 0.04 0.04 0.06 0.4 
        
PLAC 0.96 0.96 0.93 0.9 0.89 0.85* 0.86* 
± SD 0.1 0.07 0.05 0.05 0.03 0.03 0.03 
 
*
 Significantly lower (p < 0.05) than pre-exercise values 
 
There were no significant main effects for condition, time, or the condition x time 
interaction for mean energy expenditure.  There were significant main effects for 
condition and time, but not the condition x time interaction, for energy expended that was 
of carbohydrate origin (p < 0.05).  There was also a significant main effect for time in 
regards to energy expended from fat sources (p < 0.05), but there were not significant 
main effects for condition or the condition x time interaction.  Data in regards to energy 
expenditure can be seen in Tables 4-14, 4-15, and 4-16.  These calculations assume that 
protein contribution to energy expenditure is negligible during moderate intensity 
exercise, which is highly debatable.30, 77, 96, 154, 155 
  
Table 4-9 Mean Energy Expenditure (kcals) 
Group 0:00-0:15 0:15-0:30 0:30-0:45 0:45-1:00 1:00-1:15 1:15-1:30 
       
CHO 140.61 136.29 133.2 135.25 132.93 132.38 
± SD 20.79 19.54 26.36 21.76 24.86 27.95 
       
BCAA 137.03 132.58 128.17 127.81 127.38 130.37 
± SD 22.4 19.27 21.05 24.97 26.68 27.48 
       
PLAC 135.92 138.43 127.54 129.33 125.36 126.01 





Table 4-10 Mean Energy Expenditure from Carbohydrate Oxidation (kcals) 
Group 0:00-0:15 0:15-0:30 0:30-0:45 0:45-1:00 1:00-1:15 1:15-1:30 
       
CHO 130.45 119.77 98.59 108.3 86.52* 88.56* 
± SD 25.27 12.85 31.56 26.68 27.46 36.4 
       
BCAA 117.27 105.2 90.89* 74.39*^ 76.66*^ 81.87*^ 
± SD 34.5 22.9 28.53 23.53 31.88 24.75 
       
PLAC 114.54 111.63 88.90* 82.72*^ 68.70*^ 69.92*^ 
± SD 40.98 38.87 38.88 24.84 23.56 29.23 
 
*
 Significantly less (p < 0.05) than the 0:00-0:15 time period; 
^
 Significantly less (p < 0.05) than the 0:15-0:30 time period 
 
Table 4-11 Mean Energy Expenditure from Fat Oxidation (kcals) 
Group 0:00-0:15 0:15-0:30 0:30-0:45 0:45-1:00 1:00-1:15 1:15-1:30 
       
CHO 10.16 16.52 34.61* 26.94 46.41*^ 43.82*^ 
± SD 15.48 9.05 28.09 21.38 33.94 33.12 
       
BCAA 19.76 27.37 37.28 53.42*^ 50.71*^ 48.50*^ 
± SD 22.44 16.76 17.65 21.36 29.04 22.2 
       
PLAC 21.37 26.8 38.64 46.61* 56.66*^ 56.09*^ 
± SD 21.78 21.32 23.34 16.23 17.11 15.97 
 
*
 Significantly greataer (p < 0.05) than the 0:00-0:15 time period; 
^
 Significantly greater (p < 0.05) than the 0:15-0:30 time period 
 
Glucose and BCAA Results 
Repeated measures ANOVA did not show significant main effects for condition, 
time, or the condition x time interaction in regards to plasma glucose concentrations (p > 







Table 4-12 Mean Plasma Glucose Concentration (mg/dL) 
Trial Pre Post 
   
CHO 98.96 107.52 
± SD 13.31 17.45 
   
BCAA 102.36 102.34 
± SD 14.72 18.84 
   
PLAC 105.69 99.65 
± SD 14.62 17.31 
 
Repeated measures ANOVA revealed significant main effects for condition, time, and the 
condition x time interaction in regards to all the BCAA (p < 0.01).  The BCAA trial 
showed increased post-exercise concentrations of leucine, isoleucine, and valine as 
compared to the CHO and Placebo trials (p < 0.01).  The BCAA concentrations in the 
CHO and Placebo trials were reduced post-exercise compared to pre-exercise while in the 
BCAA trial greater post-exercise values were found (p < 0.01).  Mean plasma 
concentrations of the BCAA are presented in Table 4-15, 4-16, and 4-17.   
 
Table 4-13 Mean Plasma Leucine Concentration ( mol/L) 
Trial Pre Post 
   
CHO 133.4 126.1# 
± SD 22.1 19.2 
   
BCAA 133.6 721.3*^ 
± SD 18.5 113.8 
   
PLAC 141 110.6# 
± SD 21.3 15.8 
 
*
 Significantly greater (p < 0.01) than the CHO and PLAC trials; 
#
 Significantly lower (p < 0.01) than pre-exercise value; 
^






Table 4-14 Mean Plasma Isoleucine Concentration ( mol/L) 
Trial Pre Post 
   
CHO 65.8 61.2# 
± SD 16.8 16.3 
   
BCAA 67.1 581.2*^ 
± SD 15.1 112.1 
   
PLAC 69.3 53.6# 
± SD 14.6 9.8 
 
*
 Significantly greater (p < 0.01) than the CHO and PLAC trials; 
#
 Significantly lower (p < 0.01) than pre-exercise value; 
^
 Significantly greater (p < 0.01) than the pre-exercise value 
 
Table 4-15 Mean Plasma Valine Concentration ( mol/L) 
Trial Pre Post 
   
CHO 257.1 241.4# 
± SD 31.3 30 
   
BCAA 262.7 1154.2*^ 
± SD 27.9 170.5 
   
PLAC 253 207.7# 
± SD 33.5 29.1 
 
*
 Significantly greater (p < 0.01) than the CHO and PLAC trials; 
#
 Significantly lower (p < 0.01) than pre-exercise value; 
^
 Significantly greater (p < 0.01) than the pre-exercise value 
 
Order Effect 
 In order to determine whether any adaptations occurred between the trials, the 
order effect (Trial 1 vs. Trial 2 vs. Trial 3) was tested.  Analyses of variance did not 
reveal any significant main effects in regards to CK, LDH, leg flexion/extension torque, 
ratings of perceived soreness, and time trial performance (p > 0.05).  The results of the 
order effect tests are presented in Table 4-18. 
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Table 4-16 Mean Order Effects 
Trial Pre Post Post-4 Post-24 Post-48 
CK      
1 141.16 187.1 297.91 471.42 349.28 
± SD 42.4 64.77 164.98 407.63 292.96 
2 145.22 176.37 259.88 410.9 340.59 
± SD 47.54 55.61 76.6 207.73 162.06 
3 140.2 205.42 268.54 385.46 296.44 
± SD 37.94 82.76 81.95 165.07 111.49 
      
LDH      
1 145.48 190.75 209.11 170.47 157.42 
± SD 43.22 55.88 67.94 49.53 43.5 
2 145.07 167.01 189.8 162.3 153.29 
± SD 37.96 45.77 48.23 42.95 40.81 
3 143.95 169.07 191.44 163.7 154.88 
± SD 38.24 43.46 41.6 42.74 37.27 
      
Extension      
1 158.49 101.34 122.61 118.36 121.51 
± SD 24.32 12.09 16.97 12.28 11.81 
2 158.46 111.44 124.41 122.29 123.51 
± SD 21.64 22.47 24.36 24.64 26.57 
3 158.34 109.76 123.72 126.13 126.89 
± SD 23.55 28.63 30.37 28.84 20.71 
      
Flexion      
1 121.18 92.11 97.54 92.42 95.02 
± SD 27.82 15.61 24.05 15.07 16.38 
2 120.24 99.44 89.37 88.11 93 
± SD 25.16 20.25 18.84 16.1 18.27 
3 120.51 93.51 95.82 97.35 97.68 
± SD 24.64 22.34 22.21 21.12 20.11 
      
Soreness      
1 1 1 1 2 1.44 
± SD 0 0 0 0.87 0.53 
2 1 1 1 2.56 1.22 
± SD 0 0 0 1.33 0.44 
3 1 1 1 1.78 1.33 





Table 4-15 - continued. 
Time Trial   
1 4.39 
± SD 0.62 
2 4.29 
± SD 0.36 
3 4.24 




























DISCUSSION AND CONCLUSIONS 
 
 The purpose of the present study was to determine if BCAA supplementation 
during endurance exercise would attenuate indirect indicators of muscle damage, improve 
aerobic performance, and decrease RPE as compared to both isocaloric and placebo 
beverages.  It was hypothesized that BCAA supplementation would decrease post-
exercise concentrations of CK, LDH, the loss of MVC leg extension and flexion torque, 
and ratings of perceived soreness.  It was also hypothesized that BCAA supplementation 
would improve time-trial performance and decrease RPE.  The present data suggest that 
BCAA supplementation attenuates muscle damage during prolonged endurance exercise 
in unfit, college-aged males, but does not affect performance.   
 
Blood Markers of Muscle Damage 
The strongest evidence from the present study to suggest BCAA's role in reducing 
muscle damage is from the blood concentrations of muscle enzymes measured.  As noted 
in the Results section, all blood markers were adjusted for plasma volume shifts.  
Subjects ingested a total of 80 fluid ounces in a thermoneutral environment immediately 
before and during the exercise trial.  The changes in plasma volume pre- to post-exercise 
may have been attenuated by the fluid intake before and during exercise. 
BCAA ingestion resulted in decreased CK concentrations as compared to the 
Placebo trial at 4, 24, and 48 hours post-exercise, as well as compared to the CHO trial at 
24-hours.  Interestingly, the CHO trial also reduced the CK concentrations more than the 
Placebo trial at 24 and 48 hours.  Although these results indicate that BCAA intake may 
be a superior choice, it is possible that energy intake during exercise, regardless of the 
macronutrient composition, will result in an attenuated CK response post-endurance 
exercise as it decreases the need for muscle protein oxidation.28, 32, 74, 148 However, fat 
ingestion during endurance exercise has not been investigated in this regard.  The CK 
responses in the present study are in agreement with the CK results of Coombes and 
McNaughton (2000) and Saunders et al. (2004) in regards to the effectiveness of BCAA 
or protein supplementation during endurance cycling.42, 127 
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In regards to the CK response, the normally large intersubject variability resulted 
in large standard deviations, making significant differences more difficult to attain.36 
Avoiding the bias an outlier may have on a single group response was the initial reason 
for the repeated-bout design in the present study.112 Because the repeated bout effect may 
last up to 6 months, a repeated-bout design could also create a large variability within 
each trial, but provides a more powerful design.8, 31, 42, 83, 120, 129 However, a test of the 
trial order effect showed no significant differences in the CK response in this study.  At 
the CK peak (24-hours post-exercise), the mean difference between the first and third 
trial was 85.96 U/L.  Since this difference, as well as the differences in all other time-
points, may have occurred by chance (p > 0.05), it is suggested that the CK repeated-bout 
effect was not a confounding factor in the present study.  Furthermore, eight weeks may 
be a long enough duration between cycling trials in untrained subjects to avoid the 
repeated-bout effect in future studies. 
Although significant differences were found in regards to CK, the effect size 
appears (as specific data were not reported) much lower than in the Saunders et al. 
study.127 The CHO+protein group in the Saunders et al. study received 139 kilocalories of 
energy more during the trial than the CHO alone group that may account for the larger 
effect size.  However, it is also possible that amino acids and CHO ingestion have a 
synergistic effect in preventing damage.45, 66, 67, 86, 103, 130, 143 
Because CHO intake during exercise produces a small but significant insulin 
response that would aid BCAA entry into the muscle cell, amino acid ingestion may not 
attenuate muscle damage as effectively without the co-ingestion of CHO.45, 86 An 
approximately 10-fold increase in insulin sensitivity is reported when CHO is co-infused 
with BCAA as compared to CHO alone.66 Leucine ingestion alone has also been shown 
to stimulate an insulin response.60 Consequently, the small increases in insulin from CHO 
feeding during exercise will most likely have a more dramatic effect on BCAA uptake in 
leg muscles if the CHO is co-ingested with BCAA.  It has also been concluded in several 
studies that increases in muscle protein synthesis after feeding animals or humans are 
mediated by temporary elevations in insulin and AA concentrations, therefore it can be 
speculated that increases in both could mediate protein metabolism during exercise as 
well.67, 103, 143 Frexes-Steed et al. (1992) found that both insulin and AA, most notably 
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leucine, decrease rates of proteolysis in humans.62 It also appears that insulin's 
suppression of proteolysis is greatly attenuated when plasma AA concentrations are 
low.59, 63 Additionally, the ingestion of protein with CHO has been shown to increase 
CHO absorption rates as compared to CHO ingestion alone which gives further evidence 
to a potential synergistic effect.130 
 The LDH results support the hypothesis that BCAA supplementation would 
alleviate some degree of damage, as the level at 4-hours post-exercise was significantly 
lower than the Placebo trial.  It is assumed that LDH concentrations are elevated when 
there is damage to the muscle because an increase in the permeability of muscle cell 
membranes, or the complete disruption of them, allows muscle enzymes to leak into the 
blood or lymphatic system.76, 106 In partial contrast to the present results, Coombes and 
McNaughton (2000) reported reduced LDH concentrations in a BCAA-supplemented 
group as compared to a placebo group for 5-days post-exercise.42   However, subjects in 
the present study exercised for a shorter duration (15 minutes less) at a lower intensity 
(55% VO2 max vs. 70% VO2 max) than in the Coombes and McNaughton (2000) study.  
As LDH is a less sensitive marker of muscle damage than CK, a higher exercise intensity 
or longer duration may have been needed to find greater differences between groups.37, 110  
The BCAA trial was the only trial to show elevated LDH at 24-hours even though 
the CHO and Placebo trials had higher values.  This is because Mauchly's Test of 
Sphericity was violated in the CHO and Placebo trials.  When sphericity is assumed, as in 
the BCAA trial, the mean square of the error is reduced as compared to when sphericity 
cannot be assumed, making it easier to find significant differences between time points. 
Although the present study is the first to provide evidence through muscle enzyme 
data, there is research to suggest that glucose ingestion during endurance exercise may 
decrease muscle protein breakdown.45, 152 In a recent study, van Hamont et al. (2005) 
reported that protein catabolism, as determined indirectly by sweat and urine urea 
excretion, is significantly reduced during endurance cycling when glucose is fed.152 
Additionally, glucose infusion with AA significantly lowers ureagenesis as compared to 
AA infusion alone in dogs.73 The present study found that CHO ingestion decreases CK 
levels at 24 and 48-hours post-endurance exercise as compared to a non-caloric placebo.  
It is assumed that gluconeogenesis occurs to a lesser extent when glucose is fed.73, 152 
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Additionally, it has been hypothesized that reductions in TCA cycle intermediates are 
responsible for increased protein catabolism.155 Therefore, glucose ingestion during 
exercise may reduce protein catabolism because it has been shown to increase TCA cycle 
intermediates.138 Conversely, Couture et al. (2002) reported no difference in protein 
oxidation with or without glucose feeding during endurance exercise.43 Since this 
potential attenuation of damage was only seen in the CK data, the most sensitive of the 
markers used to assess muscle damage, formal conclusions should not be drawn 
regarding this issue.   
Post-exercise leg flexion and extension torques were below pre-exercise values 
with the one exception of 48-hour post-exercise flexion in the BCAA trial.  The decrease 
in torque may have resulted from several factors.  Mechanical forces during the cycling 
trial may have caused a direct disruption in muscle fiber structure and function.  
Additionally, increased permeability of the cell membrane, as seen in prolonged 
endurance exercise, results in a high calcium influx from the interstitium.  Elevated 
calcium concentrations within the muscle fiber activate proteolytic enzymes that break 
down troponin, tropomyosin, and Z-disc structure, impairing muscle function.48, 49, 85 
Although the BCAA trial had higher torque levels compared to the other two 
trials at 4, 24, and 48-hour time points in both extension and flexion, only the 48-hour 
flexion torque was significantly different.  The quadriceps are typically considered to be 
the primary agonists during cycle ergometry as they are involved in knee extension and 
hip flexion, but the knee flexors may contribute up to 10% of the total positive work.  
The biceps femoris functions as a hip extensor, the medial hamstring is primarily a knee 
flexor, and both work eccentrically to stabilize the pelvis.53, 54 Decreased muscle damage 
or an improved recovery may be responsible for the attenuation of knee flexion torque 
loss at 48-hours in the BCAA trial.  As post-exercise dietary records were not kept 
beyond 4 hours, there also may have been dietary factors that played a role in the 
recovery after the BCAA trial.57 This is less of a concern for the CK and LDH data 
because diet beyond immediately-post exercise intake has never been shown to affect 
these variables. 
In regards to isokinetic torque, one possible explanation for the lack of significant 
differences between trials is that maximal torque is primarily determined by the activity 
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of high threshold motor units (the alpha motor neuron and faster twitch muscle fibers).79 
According to the metabolic hypothesis of muscle damage, during endurance cycling the 
muscular injury should be confined primarily to lower threshold motor units (the alpha 
motor neuron and slower twitch muscle fibers).  Consequently, using a test that does not 
specifically target the muscle fiber type that incurred the most damage may not have been 
the most appropriate method.  However, there were still significant decreases in torque in 
all trials because lower threshold motor units, those assumed to have incurred the most 
damage, contribute to maximal force production. 
Subjects' ratings of perceived soreness were elevated in both the CHO and 
Placebo trials.  Although the underlying mechanisms for DOMS have not been 
elucidated, the pain response may have resulted from a general inflammatory response 
during and after exercise.  Damage-induced edema and the consequent stimulation of free 
nerve endings, or the damage-induced release of inflammatory markers (e.g. bradykinin, 
prostaglandin E2, histamine) that stimulate pain receptors may all be responsible for the 
increase in muscle soreness, although mechanisms are still not fully understood.46, 111, 114 
Subjects' ratings of perceived soreness support the hypothesis that BCAA 
supplementation did reduce muscle damage in the thigh to a greater extent than the CHO 
and placebo beverages.  BCAA supplementation prior to resistance training significantly 
reduces DOMS, however the present study is the first to report decreased post-endurance 
exercise DOMS resulting from BCAA supplementation.132 The hypothesis that energy 
intake ingested during exercise (regardless of macronutrient composition) helps to 
prevent muscle damage is not supported by these results as there were no differences 
between the CHO and Placebo trials, and all trials had returned to pre-exercise values by 
48-hours post-exercise (p > 0.05).   
Blood levels of the BCAA reflect the large dietary dose of BCAA that was given.  
Unfortunately, since the blood levels of BCAA were so high in the BCAA trial, it 
introduced a large variability within the trials making differences in BCAA 
concentrations hard to find between the CHO and Placebo trials.  BCAA intake would 
prevent the decline in the free amino acid pool that may act as a signal for muscle protein 
degradation.147 It is assumed that the removal of BCAA from the free AA pool was for 
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oxidation.77, 154 Had the cycling trial been longer in duration, differences between the 
CHO and placebo trials might have increased and significant differences been found. 
Although mechanisms were not investigated, several theories as to why BCAA 
supplementation reduces muscle damage exist.  When given before aerobic exercise, 
exogenous BCAA increase concentrations of testosterone and human growth hormone 
that results in a more anabolic environment.32, 66 Both the administration of BCAA and 
alpha-ketoisocaproate, the keto analogue of leucine, inhibit protein catabolism in vitro.28, 
148 Elevated leucine levels are also associated with enhanced activity of eukaryotic 
initiation factor 4F which plays a role in protein synthesis.6, 7 In addition, it has been 
suggested that a decrease of AA in the free muscle pool, as would occur during prolonged 
exercise, may act as a signal to promote muscle protein degradation, thereby replenishing 
the pool.147 Therefore, keeping the pool high in BCAA through supplementation may 
suppress the signal for muscle breakdown.  The decrease in protein breakdown and 
consequent attenuation of cell membrane permeability alterations are assumed to be 
responsible for the improvement in muscle damage indicators within the BCAA trial. 
The mean VO2 peak of 36.26   2.23 ml/kg/min places the subject pool in the 20th 
percentile for males age 20-29 years.2 This value may not represent true maximal VO2 
because those obtained using a cycle ergometer result in lower values than those obtained 
using a treadmill except with highly trained cyclists.142 However, it can still be assumed 
that the subjects' mean aerobic fitness is below average for their age group and gender.  
Because trained athletes are reported to have less muscle damage in response to any 
mode of exercise, the significant results of this study may not necessarily be applicable to 
all levels of athletes.37 
 
Performance and Metabolism 
A greater distance was traveled in the CHO trial than the Placebo trial, whereas 
no difference was found between the Placebo and BCAA trial.  Because ingesting more 
than 1 gram of CHO per minute does not result in any additional benefit (as intestinal 
absorption appears to be limited at approximately 60g/hour), additional non-carbohydrate 
energy may provide benefit.89 The ingestion of protein may increase CHO absorption 
rates, strengthening the argument to include BCAA in CHO beverages.130 However, one 
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concern in regards to adding BCAA to sports drinks is that BCAA ingestion may hinder 
performance due to the potential carbon drain it places on the TCA cycle.  During 
transamination, the first step in BCAA catabolism, the amino group of leucine is accepted 
by  -ketoglutarate, forming glutamate.  When pyruvate is not readily available to supply 
the alanine aminotransferase reaction, the oxidation of leucine may lead to an attenuation 
of TCA cycle flux and consequently reduced ATP turnover.154 Likewise, as pyruvate 
becomes less available, glutamine replaces alanine as the major nitrogen carrier.154 As the 
CHO trial only produced a small increase in distance traveled (0.20 km) compared to the 
BCAA trial, this carbon drain does not appear to be significant during exercise under 105 
minutes since the alanine aminotransferase reaction can compensate for the carbon loss 
when glycogen is present.154 When glycogen stores are nearly depleted and pyruvate is no 
longer available in large amounts, leucine oxidation may lead to reduced ATP turnover.  
In regards to performance, the present study indicates that there would be no deleterious 
or beneficial effects to adding BCAA to a CHO beverage under conditions in which 
sufficient muscle glycogen is present. 
Previous research found that BCAA ingestion before and during exercise leads to 
a reduced RPE during endurance exercise.47 The present study supports this finding as 
RPE was reduced during the BCAA trial at 75 and 90-minutes as compared to the 
Placebo trial.  As mechanisms underlying the central fatigue hypothesis take an extended 
duration to manifest (i.e. > 1 hour), it is not surprising that a significant difference was 
not found until 75 minutes into exercise.17 However, this reduction in RPE at 75 and 90-
minutes did not lead to an increased performance in the time trial portion of the ride.  
CHO feeding during exercise has also been shown to lower RPE as compared to a 
placebo beverage.  This reduction in RPE was observed in the present study but did not 
reach statistical signficance.149 
No differences were expected in VO2, ventilation, or heart rate.  However, the 
lack of differences does confirm that equivalent workloads were given for each steady-
state trial.  Although carbohydrate ingestion during exercise has been shown to increase 
CHO oxidation, no significant differences were found in RER.70, 88, 159 Total energy 
expenditure did not differ between trials.  The CHO trial derived a higher percentage of 
energy from carbohydrates (632.12 kcal) than the BCAA (546.28 kcal) or Placebo trials 
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(536.41 kcal).  The CHO trial derived a lower percentage of energy from fats (178.46 
kcal) than the BCAA (237.04 kcal) or Placebo trials (246.17 kcal).  When analyzed in 15-
minute bouts the differences in energy expenditure source were not significant between 
trials.  However, the main time effect confirms that as duration increased, metabolism 
began to shift away from CHO utilization and toward fat utilization in all trials. 
No significant differences were found in blood glucose concentrations.  If trends 
had continued, a longer exercise trial may have shown that CHO ingestion during 
exercise helps to better maintain glucose levels as compared to the placebo beverage.13 In 
regards to the BCAA trial, Shimomura et al. (2000) reported that BCAA feeding 
suppresses glycogen utilization in rats during exercise by increasing the activity of the 
hepatic BCKAD complex.131 This may also decrease the need for blood glucose as an 
energy source, possibly preventing a decline in blood glucose as well.  It is doubtful, 
however, that the exercise trial was too short in duration for changes in blood glucose to 
reach statistical significance as glucose levels significantly decline in highly trained 
cyclists within an hour of exercise.44 The exercise intensity (55% VO2 max) may be a 
more logical reason why within-subject differences were not seen as fat oxidation is 
favored at lower intensities of aerobic exercise.72, 119 
 
Conclusions 
BCAA supplementation before and during endurance exercise attenuates indirect 
markers of muscle damage as compared to an isocaloric, or non-caloric, non-protein 
beverage in low fit, college-aged males.  Serum concentrations of CK and LDH, ratings 
of perceived soreness, and leg flexion torque at 48-hours post-exercise all support this 
conclusion.  BCAA supplementation prevents the decline of leucine, isoleucine, and 
valine concentrations in the blood during exercise.  This may have contributed to a 
reduced degree of muscle damage but did not affect the time-trial performance.  
Therefore, the central fatigue hypothesis may not be a relevant issue in humans when 
exercise duration is less than 105 minutes at intensities of 55% VO2 max or below.  
However, BCAA supplementation did lower the RPE as compared to the placebo 
beverage at 75 and 90-minutes of steady-state exercise. 
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Glucose feeding before and during exercise also reduced post-exercise CK 
concentrations at 24 and 48-hours post-exercise as compared to a non-caloric beverage, 
and improved performance in the time trial. 
 
Future Research 
As the CHO beverage improved performance in the loaded time-trial and BCAA 
supplementation showed both physical and mental benefit without any deleterious 
effects, the addition of BCAA to CHO beverages is suggested for endurance athletes. 
However, several questions remain regarding the efficacy of BCAA 
supplementation.  The present study is the first to show that BCAA ingestion before and 
during exercise may help prevent muscle damage in comparison to an isocaloric beverage 
in untrained individuals.  This issue needs to be investigated in well-trained athletes in 
which muscle damage is normally reduced.37 The use of stable isotopic tracers would be 
of particular benefit as protein synthesis rates could be calculated for individual tissues 
via muscle biopsy samples.  Warren et al. (1999) also suggested the use of range of 
motion tests as an alternative method for assessing muscular damage, although the 
reliability of these measurements are not well established in this context.160 Additionally, 
if isokinetic muscle actions are used to evaluate the degree of muscle damage after 
endurance exercise, it may be advisable to also include a short-term local muscular 
endurance test that will better target the muscle fibers used in the exercise session than an 
MVC would. 
There is now evidence to suggest that glucose has a moderate anti-catabolic role 
in regards to muscle protein metabolism, possibly due to either a slight insulin 
stimulation or a decrease in the need for protein metabolism.152 Additionally, there is 
reason to argue that a synergistic effect exists between BCAA and glucose ingestion as 
the co-ingestion of protein increases CHO absorption rates and may favorably augment 
insulin levels.86, 130, 162 Similarly, the co-ingestion of CHO may stimulate an insulin 
response aiding BCAA entry into muscle cells, and BCAA infusion in turn dramatically 
increases insulin sensitivity.45, 66 This synergistic effect should be further investigated in 
exercising humans as many BCAA supplements are marketed for use with CHO-
electrolyte beverages.  A similar design as the present study may be used with the 
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addition of a CHO+BCAA beverage, and possibly with the exclusion of the non-caloric 
beverage.  However, an important procedural decision must be made to match the 
beverages for CHO or total energy.  If total energy is not matched, the design will face 
similar criticism as previous studies that found decreases in muscle damage resulting 
from AA ingestion, but could not conclude whether the difference was from the AA or 
additionally energy intake.42, 127 However, if performance is being investigated, CHO 
intake may be more appropriate to match than energy intake as CHO has repeatedly been 
shown to improve aerobic performance as compared to the other macronutrients.27, 102 









































APPENDIX C: HEALTH HISTORY PROFILE 
 
Health History Form 
 
 
Please indicate whether any of the following apply to you. If so, please place a check in 
the blank beside the appropriate item. Thank you. 
 
______  Hypertension or high blood pressure 
 
______  A personal OR family history of heart problems or heart disease 
 
______  Diabetes 
 
______  Orthopedic problems 
 
______  Cigarette smoking or other regular use of tobacco products 
 
______  Asthma or other chronic respiratory problems 
 
______  Recent illness, fever or Gastrointestinal Disturbances (diarrhea, nausea, 
vomiting) 
 






List any prescription medications, vitamin/nutritional supplements or over-the-counter 
medicines you routinely take or have taken in the last five days (including 
dietary/nutritional supplements, herbal remedies, cold or allergy medications, antibiotics, 






I certify that my responses to the foregoing questionnaire are true, accurate, and 
complete. 
 




APPENDIX D: RESULTS TABLES 
 
Table D-1 Mean Creatine Kinase (U/L) 
Trial Pre Post Post-4 Post-24 Post-48 
      
CHO 138.43 188.29 263.45^ 359.95#^ 289.64^ 
± SD 38.59 71.95 86.27 127.42 95.94 
      
BCAA 145.11 164.04 211.82^ 228.08^ 191.38^ 
± SD 46.63 45.35 65.5 76.14 63.13 
      
PLAC 143.04 216.56^ 351.05#^ 679.76*^ 505.30*^
± SD 42.7 76.38 133.48 312.3 234.78 
 
*
 Significantly greater (p < 0.05) than the BCAA and CHO trials; 
#
 Significantly greater (p < 0.05) than the BCAA trial;  
^
 Significantly greater (p < 0.05) than the pre-exercise value 
 
 
Table D-2 Mean Lactate Dehydrogenase (U/L) 
Trial Pre Post Post-4 Post-24 Post-48 
      
CHO 145.57 167.83^ 195.23^ 163.24 153.61 
± SD 40.64 47.58 43.56 44.81 42.38 
      
BCAA 145.24 161.31^ 163.00^ 158.82^ 150.95 
± SD 36.09 39.26 42.17 40.67 37.22 
      
PLAC 143.69 197.7 232.11*^ 174.41 161.03 
± SD 42.62 53.32 50.63 48.59 41.41 
 
*
 Significantly greater (p < 0.05) than the BCAA trial; 
^
 Significantly greater (p < 0.05) than the pre-exercise value 
 
 
Table D-3 Mean Maximal Leg Extension Torque (N-M) 
Trial Pre Post Post-4 Post-24 Post-48 
      
CHO 159.52 112.03^ 124.59^ 122.36^ 119.47^ 
± SD 22.96 28.3 25.07 23.92 13.4 
      
BCAA 157.44 108.19^ 129.59^ 124.46^ 130.31^ 
± SD 22.64 17.14 24.06 22.13 22.24 
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PLAC 158.32 102.32^ 116.56^ 119.97^ 122.13^ 
± SD 23.92 19.69 22.37 23.46 23.34 
 
^
 Significantly lower (p < 0.05) than the pre-exercise value 
 
 
Table D-4 Mean Maximal Leg Flexion Torque (N-M) 
Trial Pre Post Post-4 Post-24 Post-48 
      
CHO 119.98 96.62^ 90.91^ 92.02^ 87.90^ 
± SD 25.82 16.37 13.66 16.36 10.36 
      
BCAA 120.21 95.92^ 99.59^ 96.67^ 107.89* 
± SD 24.39 19.64 28.36 21.16 19.65 
      
PLAC 121.74 92.52^ 92.23^ 89.19^ 89.91^ 
± SD 27.4 22.86 20.7 15.26 15.9 
 
*
 Significantly greater (p < 0.05) than the CHO and PLAC trials; 
^




Table D-5 Mean Ratings of Perceived Soreness 
Trial Pre Post Post-4 Post-24 Post-48 
      
CHO 1 1 1 2.33*^ 1.33 
± SD 0 0 0 1 0.5 
      
BCAA 1 1 1 1.33 1.11 
± SD 0 0 0 0.71 0.33 
      
PLAC 1 1 1 2.67*^ 1.56 
± SD 0 0 0 0.87 0.53 
 
*
 Significantly greater (p < 0.05) than the BCAA trials; 
^















APPENDIX E: ANOVA SUMMARY TABLES 
 
 
Table E-1 Dietary Intake ANOVA Summary    
Variable F p Significance 
(p<0.05) 
n df MS 
Total Energy - Day 1 0.130 0.879 No 9 2 58519.917 
Total Energy - Day 2 0.439 0.649 No 9 2 361053.500 
Total Energy - Day 3 0.052 0.950 No 9 2 32698.240 
Total CHO - Day 1 36.906 0.836 No 9 2 3566.834 
Total CHO - Day 2 0.083 0.920 No 9 2 1939.003 
Total CHO - Day 3 0.016 0.984 No 9 2 458.205 
Total Protein - Day 1 1.440 0.257 No 9 2 571.581 
Total Protein - Day 2 0.245 0.785 No 9 2 306.698 
Total Protein - Day 3 0.408 0.669 No 9 2 313.299 
Total Fat - Day 1 0.009 0.991 No 9 2 4.856 
Total Fat - Day 2 0.725 0.495 No 9 2 558.060 
Total Fat - Day 3 0.048 0.953 No 9 2 40.785 
Vitamin C - Day 1 0.467 0.632 No 9 2 1124.407 
Vitamin C - Day 2 0.986 0.986 No 9 2 32.648 
Vitamin C - Day 3 0.848 0.848 No 9 2 361.535 
Vitamin E - Day 1 0.014 0.986 No 9 2 0.133 
Vitamin E - Day 2 0.119 0.889 No 9 2 1.102 
Vitamin E - Day 3 0.136 0.874 No 9 2 1.220 
 
 
Table E-2 CK Within-Subjects AVOVA Summary (Log 10 Transformation) 
Source F p Significance 
(p<0.05) 
n df MS 
Condition 57.198 0.000 Yes 9 1.591 0.811 
Error (Cond)         12.727 0.014 
Time 78.106 0.000 Yes 9 2.696 1.126 
Error (Time)         21.568 0.014 
Time x Cond 21.178 0.000 Yes 9 2.943 0.239 
Error (Time x Cond)         23.547 0.011 
 
 
Table E-3 CK Time-Effect ANOVA Summary (Log 10 Transformation) 
CK - CHO F p Significance 
(p<0.05) 
n df MS 
Time 33.242 0.000 Yes 9 2.100 0.446 
Error (Time)         16.797 0.013 
       
CK - BCAA F p Significance 
(p<0.05) 
n df MS 
Time 15.107 0.000 Yes 9 4 0.056 
Error (Time)         32 0.004 
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CK - PLAC F p Significance 
(p<0.05) 
n df MS 
Time 88.821 0.000 Yes 9 4 0.644 
Error (Time)         32 0.007 
 
 
Table E-4 LDH Within-Subjects ANOVA Summary     
Source F p Significance 
(p<0.05) 
n df MS 
Condition 9.105 0.002 Yes 9 1.224 12691.066 
Error (Cond)         9.796 1393.893 
Time 26.293 0.000 Yes 9 1.470 29247.154 
Error (Time)         11.760 1112.373 
Time x Cond 7.751 0.009 Yes 9 1.605 8993.946 
Error (Time x Cond)         12.839 1160.301 
 
 
Table E-5 LDH Time-Effect ANOVA Summary            
LDH - CHO F p Significance 
(p<0.05) 
n df MS 
Time 38.033 0.000 Yes 9 1.850 6968.192 
Error (Time)         14.797 183.214 
       
LDH - BCAA F p Significance 
(p<0.05) 
n df MS 
Time 9.953 0.000 Yes 9 4 509.370 
Error (Time)         32 51.178 
       
LDH - PLAC F p Significance 
(p<0.05) 
n df MS 
Time 11.566 0.004 Yes 9 1.305 26185.374 




Maximal Voluntary Leg Extension Torque Within-Subjects 
ANOVA Summary 
Source F p Significance 
(p<0.05) 
n df MS 
Condition 0.743 0.433 No 9 1.180 729.950 
Error (Cond)         9.441 982.935 
Time 45.382 0.000 Yes 9 1.691 22529.396 
Error (Time)         13.526 496.435 
Time x Cond 1.227 0.321 No 9 3.209 321.700 






Maximal Voluntary Leg Extension Torque Time-Effect ANOVA 
Summary 
Extension - CHO F p Significance 
(p<0.05) 
n df MS 
Time 16.204 0.000 Yes 9 4 3069.675 
Error (Time)         32 189.443 
       
Extension - BCAA F p Significance 
(p<0.05) 
n df MS 
Time 25.096 0.000 Yes 9 4 2834.147 
Error (Time)         32 112.934 
       
Extension - PLAC F p Significance 
(p<0.05) 
n df MS 
Time 32.909 0.000 Yes 9 1.588 9765.699 




Maximal Voluntary Leg Flexion Torque Within-Subjects ANOVA 
Summary 
Source F p Significance 
(p<0.05) 
n df MS 
Condition 2.926 0.083 No 9 2 685.310 
Error (Cond)         16 234.176 
Time 29.733 0.000 Yes 9 4 3781.370 
Error (Time)         32 127.178 
Time x Cond 2.617 0.015 Yes 9 8 195.389 




Maximal Voluntary Leg Flexion Torque Time-Effect ANOVA 
Summary 
Flexion - CHO F p Significance 
(p<0.05) 
n df MS 
Time 11.636 0.000 Yes 9 4 1511.099 
Error (Time)         32 129.868 
       
Flexion - BCAA F p Significance 
(p<0.05) 
n df MS 
Time 9.683 0.000 Yes 9 4 936.980 
Error (Time)         32 96.762 
       
Flexion - PLAC F p Significance 
(p<0.05) 
n df MS 
Time 34.583 0.000 Yes 9 1.731 3983.686 




Table E-10 Rate of Perceived Soreness Within-Subjects ANOVA Summary 
Source F p Significance 
(p<0.05) 
n df MS 
Condition 12.182 0.001 Yes 9 2 1.489 
Error (Cond)         16 0.122 
Time 22.448 0.000 Yes 9 4 6.267 
Error (Time)         32 0.279 
Time x Cond 6.727 0.000 Yes 9 8 0.822 
Error (Time x Cond)         64 0.122 
 
 
Table E-11 Rate of Perceived Soreness Time-Effect ANOVA Summary 
LDH - CHO F p Significance 
(p<0.05) 
n df MS 
Time 12.632 0.000 Yes 9 4 3.000 
Error (Time)         32 0.238 
       
LDH - BCAA F p Significance 
(p<0.05) 
n df MS 
Time 1.863 0.141 Yes 9 4 0.189 
Error (Time)         32 0.101 
       
LDH - PLAC F p Significance 
(p<0.05) 
n df MS 
Time 25.564 0.000 Yes 9 4 4.722 
Error (Time)         32 0.185 
 
 
Table E-12 Time Trial ANOVA Summary    
Variable F p Significance 
(p<0.05) 
n df MS 
Time Trial 4.297 0.025 Yes 9 2 1.091 
 
 
Table E-13 RPE Within-Subjects ANOVA Summary     
Source F p Significance 
(p<0.05) 
n df MS 
Condition 0.888 0.431 No 9 2 9.540 
Error (Cond)         16 10.748 
Time 51.121 0.000 Yes 9 6 111.393 
Error (Time)         48 2.179 
Time x Cond 3.351 0.000 Yes 9 12 3.385 






Table E-14 RPE Time-Effect ANOVA Summary (Log 10 Transformation) 
RPE - CHO F p Significance 
(p<0.05) 
n df MS 
Time 33.506 0.000 Yes 9 6 43.323 
Error (Time)         48 1.293 
       
RPE - BCAA F p Significance 
(p<0.05) 
n df MS 
Time 15.085 0.001 Yes 9 1.451 107.210 
Error (Time)         11.605 7.107 
       
RPE - PLAC F p Significance 
(p<0.05) 
n df MS 
Time 41.162 0.000 Yes 9 1.884 155.833 
Error (Time)         15.069 3.786 
 
 
Table E-15 VO2 Within-Subjects ANOVA Summary     
Source F p Significance 
(p<0.05) 
n df MS 
Condition 0.779 0.476 No 9 1.449 0.072 
Error (Cond)         11.595 0.093 
Time 0.603 0.117 No 9 2.696 0.224 
Error (Time)         21.582 0.051 
Time x Cond 0.602 0.835 No 9 4.453 0.018 
Error (Time x Cond)         96.00 0.011 
 
 
Table E-16 Ventilation Within-Subjects ANOVA Summary   
Source F p Significance 
(p<0.05) 
n df MS 
Condition 0.202 0.741 No 9 17.753 87.730 
Error (Cond)         11.129 87.730 
Time 2.719 0.097 No 9 1.974 182.583 
Error (Time)         15.793 67.162 
Time x Cond 0.602 0.895 No 9 3.312 11.597 
Error (Time x Cond)         96.00 7.932 
 
 
Table E-17 HR Within-Subjects ANOVA Summary     
Source F p Significance 
(p<0.05) 
n df MS 
Condition 1.029 0.380 No 9 2 152.683 
Error (Cond)         16 148.379 
Time 39.226 0.000 Yes 9 6 3187.257 
Error (Time)         48 81.254 
Time x Cond 0.808 0.642 No 9 12 29.670 
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Error (Time x Cond)         96 36.735 
 
 
Table E-18 HR Time-Effect ANOVA Summary       
HR - CHO F p Significance 
(p<0.05) 
n df MS 
Time 21.576 0.000 Yes 9 6 1045.630 
Error (Time)         48 48.463 
       
HR - BCAA F p Significance 
(p<0.05) 
n df MS 
Time 23.062 0.000 Yes 9 2.630 2961.233 
Error (Time)         21.043 128.401 
       
HR - PLAC F p Significance 
(p<0.05) 
n df MS 
Time 18.067 0.000 Yes 9 6 902.804 
Error (Time)         48 49.971 
 
 
Table E-19 RER Within-Subjects ANOVA Summary     
Source F p Significance 
(p<0.05) 
n df MS 
Condition 4.186 0.035 Yes 9 2 0.024 
Error (Cond)         16 0.006 
Time 26.252 0.000 Yes 9 6 0.043 
Error (Time)         48 0.002 
Time x Cond 0.849 0.600 No 9 12 0.001 
Error (Time x Cond)         96 0.001 
 
 
Table E-20 RER Time-Effect ANOVA Summary         
RER - CHO F p Significance 
(p<0.05) 
n df MS 
Time 9.937 0.000 Yes 9 6 0.011 
Error (Time)         48 0.001 
       
RER - BCAA F p Significance 
(p<0.05) 
n df MS 
Time 15.656 0.000 Yes 9 2.958 0.029 
Error (Time)         23.664 0.002 
       
RER - PLAC F p Significance 
(p<0.05) 
n df MS 
Time 15.974 0.000 Yes 9 1.990 0.056 
Error (Time)         15.919 0.003 
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Table E-21 Energy Expenditure Within-Subjects ANOVA Summary 
Source F p Significance 
(p<0.05) 
n df MS 
Condition 1.013 0.369 No 9 1.49 515.905 
Error (Cond)         11.90 509.278 
Time 3.464 0.051 No 9 2.193 900.665 
Error (Time)         17.54 259.977 
Time x Cond 0.675 0.744 No 9 3.793 110.017 
Error (Time x Cond)         30.344 162.920 
 
 
Table E-22 CHO Energy Expenditure Within-Subjects ANOVA Summary 
Source F p Significance 
(p<0.05) 
n df MS 
Condition 3.742 0.046 Yes 9 2 4162.970 
Error (Cond)         16 1112.354 
Time 17.628 0.000 Yes 9 5 8322.463 
Error (Time)         40 472.126 
Time x Cond 1.627 0.114 No 9 10 306.924 
Error (Time x Cond)         80 188.701 
 
 
Table E-23 CHO Energy Expenditure Time-Effect ANOVA Summary     
Energy - CHO F p Significance 
(p<0.05) 
n df MS 
Time 9.099 0.001 Yes 9 2.598 5296.458 
Error (Time)         20.784 582.118 
       
Energy - BCAA F p Significance 
(p<0.05) 
n df MS 
Time 9.949 0.000 Yes 9 5 2621.587 
Error (Time)         40 263.500 
       
Energy - PLAC F p Significance 
(p<0.05) 
n df MS 
Time 12.564 0.000 Yes 9 5 3562.631 
Error (Time)         40 283.555 
 
 
Table E-24 Fat Energy Expenditure Within-Subjects ANOVA Summary 
Source F p Significance 
(p<0.05) 
n df MS 
Condition 2.660 0.101 No 9 2 2025.261 
Error (Cond)         16 761.251 
Time 15.060 0.000 Yes 9 5 5203.120 
Error (Time)         40 345.500 
Time x Cond 1.431 0.182 No 9 10 192.944 
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Error (Time x Cond)         80 134.836 
 
 
Table E-25 Fat Energy Expenditure Time-Effect ANOVA Summary     
Energy - CHO F p Significance 
(p<0.05) 
n df MS 
Time 8.564 0.000 Yes 9 5 1918.911 
Error (Time)         40 224.062 
       
Energy - BCAA F p Significance 
(p<0.05) 
n df MS 
Time 10.084 0.000 Yes 9 5 1695.738 
Error (Time)         40 168.160 
       
Energy - PLAC F p Significance 
(p<0.05) 
n df MS 
Time 8.856 0.000 Yes 9 5 1974.359 
Error (Time)         40 222.952 
 
 
Table E-26 Glucose Within-Subjects ANOVA Summary   
Source F p Significance 
(p<0.05) 
n df MS 
Condition 0.055 0.947 No 9 2 3.650 
Error (Cond)         16 66.203 
Time 0.066 0.804 No 9 1 9.338 
Error (Time)         8 142.454 
Time x Cond 3.134 0.071 No 9 2 242.454 
Error (Time x Cond)         16 77.363 
 
 
Table E-27 Leucine Within-Subjects ANOVA Summary       
Source F p Significance 
(p<0.01) 
n df MS 
Condition 229.702 0.000 Yes 9 1.005 1072256.935 
Error (Cond)         8.044 4668.043 
Time 203.818 0.000 Yes 9 1.000 453566.685 
Error (Time)         8.000 2225.352 
Time x Cond 298.970 0.000 Yes 9 1.004 1100385.662 
Error (Time x Cond)         8.033 3680.585 
 
 
Table E-28 Isoleucine Within-Subjects ANOVA Summary   
Source F p Significance 
(p<0.01) 
n df MS 
Condition 211.006 0.000 Yes 9 2 410836.722 
Error (Cond)         16 1947.035 
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Time 197.134 0.000 Yes 9 1 365560.167 
Error (Time)         8 1854.375 
Time x Cond 217.928 0.000 Yes 9 2 412527.056 
Error (Time x Cond)         16 1892.951 
 
 
Table E-29 Valine Within-Subjects ANOVA Summary     
Source F p Significance 
(p<0.01) 
n df MS 
Condition 219.005 0.000 Yes 9 1.008 2617823.882 
Error (Cond)         8.064 11953.275 
Time 173.047 0.000 Yes 9 1.000 1034733.796 
Error (Time)         8.000 5979.505 
Time x Cond 209.753 0.000 Yes 9 1.005 2539216.438 
Error (Time x Cond)         8.042 12105.741 
 
 
Table E-30 CK Order Effect ANOVA Summary    
Time F p Significance 
(p<0.05) 
n df MS 
Pre 0.007 0.993 No 9 2 0.000 
Post 0.285 0.754 No 9 2 0.007 
Post-4 0.029 0.972 No 9 2 0.001 
Post-24 0.030 0.970 No 9 2 0.002 
Post-48 0.132 0.877 No 9 2 0.008 
 
 
Table E-31 LDH Order Effect ANOVA Summary      
Time F p Significance 
(p<0.05) 
n df MS 
Pre 0.004 0.996 No 9 2 5.654 
Post 0.657 0.527 No 9 2 1557.297 
Post-4 0.357 0.704 No 9 2 1031.638 
Post-24 0.920 0.920 No 9 2 171.835 
Post-48 0.977 0.977 No 9 2 38.960 
 
 
Table E-32 Leg Extension Torque Order Effect ANOVA Summary  
Time F p Significance 
(p<0.05) 
n df MS 
Pre 0.000 1.000 No 9 2 0.051 
Post 0.591 0.591 No 9 2 263.335 
Post-4 0.012 0.988 No 9 2 7.382 
Post-24 0.257 0.776 No 9 2 136.119 




Table E-33 Leg Flexion Torque Order Effect ANOVA Summary  
Time F p Significance 
(p<0.05) 
n df MS 
Pre 0.003 0.997 No 9 2 2.080 
Post 0.355 0.705 No 9 2 136.489 
Post-4 0.352 0.707 No 9 2 167.274 
Post-24 0.619 0.547 No 9 2 192.244 
Post-48 0.148 0.864 No 9 2 49.534 
 
 
Table E-34 Rate of Perceived Soreness Order Effect ANOVA Summary  
Time F p Significance 
(p<0.05) 
n df MS 
Pre . . No 9 2 0.000 
Post . . No 9 2 0.000 
Post-4 . . No 9 2 0.000 
Post-24 1.458 0.253 No 9 2 0.253 
Post-48 0.462 0.636 No 9 2 0.636 
 
 
Table E-35 Time Trial Order Effect ANOVA Summary   
  F p Significance 
(p<0.05) 
n df MS 



















APPENDIX F: PAIRED SAMPLE T-TEST TABLES 
 
Table F-1 Paired samples t-test of the leucine within-group effect    
    Mean S.D. Std. Error Mean t df Significance (p<0.01)
Pair 1 CHO-Pre 7.3 4.9 1.62 4.51 8 Yes 
  CHO-Post           (2-tailed) 
Pair 2 BCAA-Pre -587.7 108.5 36.16 -16.25 8 Yes 
  BCAA-Post           (2-tailed) 
Pair 3 PLAC-Pre 30.4 7.3 2.42 12.57 8 Yes 
  PLAC-Post           (2-tailed) 
 
 
Table F-2 Paired samples t-test of the isoleucine within-group effect   
    Mean S.D. Std. Error Mean t df Significance (p<0.01)
Pair 1 CHO-Pre 4.7 3.8 1.27 3.68 8 Yes 
  CHO-Post           (2-tailed) 
Pair 2 BCAA-Pre -514.1 105.8 35.28 -14.57 8 Yes 
  BCAA-Post           (2-tailed) 
Pair 3 PLAC-Pre 15.8 8.1 2.71 5.83 8 Yes 
  PLAC-Post           (2-tailed) 
 
 
Table F-3 Paired samples t-test of the valine within-group effect    
    Mean S.D. Std. Error Mean t df Significance (p<0.01)
Pair 1 CHO-Pre 15.7 9.7 3.24 4.83 8 Yes 
  CHO-Post           (2-tailed) 
Pair 2 BCAA-Pre -891.6 189.9 63.32 -14.08 8 Yes 
  BCAA-Post           (2-tailed) 
Pair 3 PLAC-Pre 45.3 11.1 3.69 12.28 8 Yes 














APPENDIX G: TUKEY POST-HOC ANALYSES 
 





















2.13 CHO-Pre 0     0.01       
2.25 CHO-Post   0     -0.05     
2.40 CHO-4    0      -0.10   
2.53 CHO-24     0       -0.19  
2.44 CHO-48      0       -0.18
2.14 BCAA-Pre       0       
2.20 BCAA-Post             0     
2.30 BCAA-4               0   
2.34 BCAA-24                 0  
2.26 BCAA-48             0
2.14 PLAC-Pre 0.01     0.00       
2.31 PLAC-Post   0.06     0.11     
2.52 PLAC-4    0.12      0.22   
2.80 PLAC-24     0.27       0.46  
2.67 PLAC-48      0.23       0.41




Tukey HSD multiple comparison test of the CK time-
effect 








2.13 CHO-Pre 0 0.12 0.27 0.40 0.31
2.25 CHO-Post  0 0.15 0.28 0.19
2.40 CHO-4   0 0.13 0.04
2.53 CHO-24    0 -0.09
2.44 CHO-48     0














2.14 BCAA-Pre 0 0.06 0.16 0.20 0.12
2.20 BCAA-Post  0 0.10 0.14 0.06
2.30 BCAA-4   0 0.04 -0.04
2.34 BCAA-24    0 -0.08
2.26 BCAA-48     0














2.14 PLAC-Pre 0 0.16 0.38 0.66 0.53
2.31 PLAC-Post  0 0.21 0.49 0.36
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2.52 PLAC-4   0 0.28 0.15
2.80 PLAC-24    0 -0.13
2.67 PLAC-48     0
Critical difference = 0.11   
 
 
Table G-3 Tukey HSD multiple comparison test of the LDH within-subjects effect    


















145.57 CHO-Pre 0     -0.33       
167.83 CHO-Post   0     -6.52     
195.23 CHO-4    0      -32.23   
163.24 CHO-24     0       -4.42  
153.61 CHO-48      0       -2.66
145.24 BCAA-Pre       0       
161.31 BCAA-Post             0     
163.00 BCAA-4               0   
158.82 BCAA-24                 0  
150.95 BCAA-48             0
143.69 PLAC-Pre -1.88     -1.55       
197.70 PLAC-Post   29.87     36.39     
232.11 PLAC-4    36.88      69.11   
174.41 PLAC-24     11.17       15.59  
161.03 PLAC-48      7.42       10.08




Tukey HSD multiple comparison test of the LDH time-
effect 








145.57 CHO-Pre 0 22.26 49.66 17.67 8.04 
167.83 CHO-Post  0 27.40 -4.59 -14.22 
195.23 CHO-4   0 -31.99 -41.62 
163.24 CHO-24    0 -9.63 
153.61 CHO-48     0 














145.24 BCAA-Pre 0 16.07 17.76 13.58 5.71 
161.31 BCAA-Post  0 1.69 -2.49 -10.36 
163.00 BCAA-4   0 -4.18 -12.05 
158.82 BCAA-24    0 -7.87 
150.95 BCAA-48     0 















143.69 PLAC-Pre 0 54.01 88.42 30.72 17.34 
197.70 PLAC-Post  0 34.41 -23.29 -36.67 
232.11 PLAC-4   0 -57.70 -71.08 
174.41 PLAC-24    0 -13.38 
161.03 PLAC-48     0 




Tukey HSD multiple comparison test of the leg 
extension torque time-effect 








159.52 CHO-Pre 0 -47.49 -34.93 -37.17 -40.05 
112.03 CHO-Post  0 12.56 10.33 7.44 
124.59 CHO-4   0 -2.23 -5.12 
122.36 CHO-24    0 -2.89 
119.47 CHO-48     0 














157.44 BCAA-Pre 0 -49.25 -27.85 -32.98 -27.13 
108.19 BCAA-Post  0 21.4 16.27 22.12 
129.59 BCAA-4   0 -5.13 0.72 
124.46 BCAA-24    0 5.85 
130.31 BCAA-48     0 














158.32 PLAC-Pre 0 -56.00 -41.76 -38.35 -36.19 
102.32 PLAC-Post  0 14.24 17.65 19.81 
116.56 PLAC-4   0 3.41 5.57 
119.97 PLAC-24    0 2.16 
122.13 PLAC-48     0 
Critical difference = 32.90    
 
 
Table G-6 Tukey HSD multiple comparison test of the leg flexion torque within-subjects effect 


















119.98 CHO-Pre 0     0.23       
96.62 CHO-Post   0     -0.70     
90.91 CHO-4    0      8.68   
92.02 CHO-24     0       4.65  
87.90 CHO-48      0       19.99
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120.21 BCAA-Pre       0       
95.92 BCAA-Post             0     
99.59 BCAA-4               0   
96.67 BCAA-24                 0  
107.89 BCAA-48             0
121.74 PLAC-Pre 1.76     1.53       
92.52 PLAC-Post   -4.10     -3.40     
92.23 PLAC-4    1.32      -7.36   
89.19 PLAC-24     -2.83       -7.48  
89.91 PLAC-48      2.01       -17.98




Tukey HSD multiple comparison test of the leg flexion 
torque time-effect 








119.98 CHO-Pre 0 -23.36 -29.07 -27.96 -32.08 
96.62 CHO-Post  0 -5.71 -4.60 -8.72 
90.91 CHO-4   0 1.11 -3.01 
92.02 CHO-24    0 -4.12 
87.90 CHO-48     0 














120.21 BCAA-Pre 0 -24.29 -20.62 -23.54 -12.32 
95.92 BCAA-Post  0 3.67 0.75 11.97 
99.59 BCAA-4   0 -2.92 8.30 
96.67 BCAA-24    0 11.22 
107.89 BCAA-48     0 














121.74 PLAC-Pre 0 -29.22 -29.51 -32.55 -31.83 
92.52 PLAC-Post  0 -0.29 -3.33 -2.61 
92.23 PLAC-4   0 -3.04 -2.32 
89.19 PLAC-24    0 0.72 
89.91 PLAC-48     0 




Tukey HSD multiple comparison test of the rate of perceived soreness within-subjects 
effect  


















1.00 CHO-Pre 0     0.00       
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1.00 CHO-Post   0     0.00     
1.00 CHO-4    0      0.00   
2.33 CHO-24     0       -1.00  
1.33 CHO-48      0       -0.22
1.00 BCAA-Pre       0       
1.00 BCAA-Post             0     
1.00 BCAA-4               0   
1.33 BCAA-24                 0  
1.11 BCAA-48             0
1.00 PLAC-Pre 0.00     0.00       
1.00 PLAC-Post   0.00     0.00     
1.00 PLAC-4    0.00      0.00   
2.67 PLAC-24     0.34       1.34  
1.56 PLAC-48      0.23       0.45




Tukey HSD multiple comparison test of the rate of 
perceived soreness time-effect 








1.00 CHO-Pre 0 0.00 0.00 1.33 0.33
1.00 CHO-Post  0 0.00 1.33 0.33
1.00 CHO-4   0 1.33 0.33
2.33 CHO-24    0 -1.00
1.33 CHO-48     0














1.00 BCAA-Pre 0 0.00 0.00 0.33 0.11
1.00 BCAA-Post  0 0.00 0.33 0.11
1.00 BCAA-4   0 0.33 0.11
1.33 BCAA-24    0 -0.22
1.11 BCAA-48     0














1.00 PLAC-Pre 0 0.00 0.00 1.67 0.56
1.00 PLAC-Post  0 0.00 1.67 0.56
1.00 PLAC-4   0 1.67 0.56
2.67 PLAC-24    0 -1.11
1.56 PLAC-48     0
Critical difference = 0.59   
 
 
Table G-10 Tukey HSD multiple comparison test of 
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the time trial 
MEANS   CHO BCAA PLAC 
4.6 CHO 0 -0.2 -0.7
4.4 BCAA   0 -0.5
3.9 PLAC    0




11 Tukey HSD multiple comparison test of the RPE time-effect    
MEANS   CHO-0:00 CHO-0:15 CHO-0:30 CHO-0:45 CHO-1:00 CHO-1:15 CHO-1:30 
10.56 CHO-0:00 0 2.55 2.00 5.00 5.66 15.77 6.00
13.11 CHO-0:15   0 1.45 2.45 3.11 3.22 3.45
14.56 CHO-0:30    0 1.00 1.66 1.77 2.00
15.56 CHO-0:45     0 0.66 0.77 1.00
16.22 CHO-1:00      0 0.11 0.34
16.33 CHO-1:15        0 0.23
16.56 CHO-1:30         0
Critical difference = 1.66       
         
MEANS   BCAA-0:00 BCAA-0:15 BCAA-0:30 BCAA-0:45 BCAA-1:00 BCAA-1:15 BCAA-1:30
10.89 BCAA-0:00 0 2.22 4.11 4.22 4.67 4.33 4.22
13.11 BCAA-0:15   0 1.89 2.00 2.45 2.11 2.00
15.00 BCAA-0:30    0 0.11 0.56 0.22 0.11
15.11 BCAA-0:45     0 0.45 0.11 0.00
15.56 BCAA-1:00      0 -0.34 -0.45
15.22 BCAA-1:15        0 -0.11
15.11 BCAA-1:30         0
Critical difference = 4.40       
      
MEANS   PLAC-0:00 PLAC-0:15 PLAC-0:30 PLAC-0:45 PLAC-1:00 PLAC-1:15 PLAC-1:30
11.22 PLAC-0:00 0 1.78 3.67 4.11 4.67 5.89 6.78
13.00 PLAC-0:15   0 1.89 2.33 3.89 4.11 5.00
14.89 PLAC-0:30    0 0.44 1.00 2.22 3.11
15.33 PLAC-0:45     0 0.56 1.78 2.67
15.89 PLAC-1:00      0 1.22 2.11
17.11 PLAC-1:15        0 0.89
18.00 PLAC-1:30         0




12 Tukey HSD multiple comparison test of the HR time-effect    
MEANS   CHO-0:00 CHO-0:15 CHO-0:30 CHO-0:45 CHO-1:00 CHO-1:15 CHO-1:30 
127.22 CHO-0:00 0 24.67 29.45 26.56 31.11 27.89 31.11
151.89 CHO-0:15   0 4.78 1.89 3.67 3.22 6.44
156.67 CHO-0:30    0 -2.89 -1.11 -1.56 1.66
153.78 CHO-0:45     0 1.78 1.33 4.55
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155.56 CHO-1:00      0 3.22 2.77
155.11 CHO-1:15        0 3.22
158.33 CHO-1:30         0
Critical difference = 10.19       
         
MEANS   BCAA-0:00 BCAA-0:15 BCAA-0:30 BCAA-0:45 BCAA-1:00 BCAA-1:15 BCAA-1:30
122.78 BCAA-0:00 0 23.33 30.00 28.33 28.22 35.44 34.22
146.11 BCAA-0:15   0 6.67 5.00 4.89 12.11 10.89
152.78 BCAA-0:30    0 -1.67 -1.78 5.44 4.22
151.11 BCAA-0:45     0 -0.11 7.11 5.89
151.00 BCAA-1:00      0 7.22 6.00
158.22 BCAA-1:15        0 -1.22
157.00 BCAA-1:30         0
Critical difference = 17.45       
      
MEANS   PLAC-0:00 PLAC-0:15 PLAC-0:30 PLAC-0:45 PLAC-1:00 PLAC-1:15 PLAC-1:30
127.22 PLAC-0:00 0 18.22 25.67 25.11 24.56 27.78 28.56
145.44 PLAC-0:15   0 7.45 6.89 6.34 9.56 10.34
152.89 PLAC-0:30    0 -0.56 -1.11 2.11 2.89
152.33 PLAC-0:45     0 -0.55 2.67 3.45
151.78 PLAC-1:00      0 3.22 4.00
155.00 PLAC-1:15        0 0.78
155.78 PLAC-1:30         0




13 Tukey HSD multiple comparison test of the RER time-effect    
MEANS   CHO-0:00 CHO-0:15 CHO-0:30 CHO-0:45 CHO-1:00 CHO-1:15 CHO-1:30 
0.99 CHO-0:00 0 0.00 -0.02 -0.06 -0.06 -0.09 -0.07
0.99 CHO-0:15   0 -0.02 -0.06 -0.06 -0.09 -0.07
0.97 CHO-0:30    0 -0.04 -0.04 -0.04 -0.05
0.93 CHO-0:45     0 0.00 -0.03 -0.01
0.93 CHO-1:00      0 -0.03 -0.01
0.90 CHO-1:15        0 0.02
0.92 CHO-1:30         0
Critical difference = 0.05       
         
MEANS   BCAA-0:00 BCAA-0:15 BCAA-0:30 BCAA-0:45 BCAA-1:00 BCAA-1:15 BCAA-1:30
0.97 BCAA-0:00 0 -0.01 -0.03 -0.07 -0.11 -0.11 -0.11
0.96 BCAA-0:15   0 -0.02 -0.06 -0.08 -0.08 -0.08
0.94 BCAA-0:30    0 -0.04 -0.06 -0.06 -0.06
0.90 BCAA-0:45     0 -0.02 -0.02 -0.02
0.88 BCAA-1:00      0 0.00 0.00
0.88 BCAA-1:15        0 0.00
0.88 BCAA-1:30         0
Critical difference = 0.07       
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MEANS   PLAC-0:00 PLAC-0:15 PLAC-0:30 PLAC-0:45 PLAC-1:00 PLAC-1:15 PLAC-1:30
0.96 PLAC-0:00 0 0.00 -0.03 -0.06 -0.07 -0.11 -0.10
0.96 PLAC-0:15   0 -0.03 -0.06 -0.07 -0.11 -0.10
0.93 PLAC-0:30    0 -0.03 -0.04 -0.08 -0.07
0.90 PLAC-0:45     0 -0.01 -0.05 -0.04
0.89 PLAC-1:00      0 -0.04 -0.03
0.85 PLAC-1:15        0 0.01
0.86 PLAC-1:30         0




Tukey HSD multiple comparison test of the CHO Energy Expenditure 
time-effect  
MEANS   0:00-0:15 0:15-0:30 0:30-0:45 0:45-1:00 1:00-1:15 1:15-1:30 
130.45 CHO-0:00-0:15 0 -10.68 -31.86 -22.15 -43.93 -41.89
119.77 CHO-0:15-0:30  0 -21.18 -11.47 -33.25 -31.21
98.59 CHO-0:30-0:45   0 9.71 -12.07 -10.03
108.30 CHO-0:45-1:00    0 -21.78 -19.74
86.52 CHO-1:00-1:15      0 2.04
88.56 CHO-1:15-1:30        0
Critical difference = 
35.79 
  
        
        
MEANS   0:00-0:15 0:15-0:30 0:30-0:45 0:45-1:00 1:00-1:15 1:15-1:30 
117.27 BCAA-0:00-
0:15 
0 -12.07 -26.38 -42.88 -40.61 -35.40
105.20 BCAA-0:15-
0:30 
 0 -14.31 -30.81 -28.54 -23.33
90.89 BCAA-0:30-
0:45 
  0 -16.50 -14.23 -9.02
74.39 BCAA-0:45-
1:00 









1:30        0
Critical difference = 
22.89 
  
        
    
MEANS   0:00-0:15 0:15-0:30 0:30-0:45 0:45-1:00 1:00-1:15 1:15-1:30 
114.54 PLAC-0:00-
0:15 
0 -2.91 -25.64 -31.82 -45.84 -44.62
111.63 PLAC-0:15-
0:30 
 0 -22.73 -28.91 -42.93 -41.71
88.90 PLAC-0:30-
0:45 
  0 -6.18 -20.20 -18.98
82.72 PLAC-0:45-
1:00 










1:30        0
Critical difference = 
23.74 
  




Tukey HSD multiple comparison test of the Fat Energy Expenditure 
time-effect  
MEANS   0:00-0:15 0:15-0:30 0:30-0:45 0:45-1:00 1:00-1:15 1:15-1:30 
10.16 CHO-0:00-0:15 0 6.36 24.45 16.78 36.25 33.66
16.52 CHO-0:15-0:30  0 18.09 10.42 29.89 27.30
34.61 CHO-0:30-0:45   0 -7.67 11.80 9.21
26.94 CHO-0:45-1:00    0 19.47 16.88
46.41 CHO-1:00-1:15      0 -2.59
43.82 CHO-1:15-1:30        0
Critical difference = 
21.11 
  
        
        
MEANS   0:00-0:15 0:15-0:30 0:30-0:45 0:45-1:00 1:00-1:15 1:15-1:30 
19.76 BCAA-0:00-
0:15 
0 7.61 17.52 33.66 30.95 28.74
27.37 BCAA-0:15-
0:30 
 0 9.91 26.05 23.34 21.13
37.28 BCAA-0:30-
0:45 
  0 16.14 13.43 11.22
53.42 BCAA-0:45-
1:00 









1:30        0
Critical difference = 
18.28 
  
        
    
MEANS   0:00-0:15 0:15-0:30 0:30-0:45 0:45-1:00 1:00-1:15 1:15-1:30 
21.37 PLAC-0:00-
0:15 
0 5.43 17.27 25.24 35.29 34.72
26.80 PLAC-0:15-
0:30 
 0 11.84 19.81 29.86 29.29
38.64 PLAC-0:30-
0:45 
  0 7.97 18.02 17.45
46.61 PLAC-0:45-
1:00 









1:30        0
Critical difference = 
21.05 
  
        
 
 
Table G-16 Tukey HSD multiple comparison test of the leucine within-subjects effect   
 93
MEANS   CHO-Pre CHO-Post BCAA-Pre BCAA-Post PLAC-Pre PLAC-Post 
133.4 CHO-Pre 0  0.2   7.6  
126.1 CHO-Post  0  595.2  -15.5
133.6 BCAA-Pre   0   7.4  
721.3 BCAA-Post    0  -610.7
141.0 PLAC-Pre      0  
110.6 PLAC-Post       0
Critical difference = 140.75      
 
 
Table G-17 Tukey HSD multiple comparison test of the isoleucine within-subjects effect  
MEANS   CHO-Pre CHO-Post BCAA-Pre BCAA-Post PLAC-Pre PLAC-Post 
65.8 CHO-Pre 0  1.3   3.5  
61.2 CHO-Post  0  520.0  -7.6
67.1 BCAA-Pre   0   2.2  
581.2 BCAA-Post    0  -527.6
69.3 PLAC-Pre      0  
53.6 PLAC-Post       0
Critical difference = 82.96       
 
 
Table G-18 Tukey HSD multiple comparison test of the valine within-subjects effect   
MEANS   CHO-Pre CHO-Post BCAA-Pre BCAA-Post PLAC-Pre PLAC-Post 
257.1 CHO-Pre 0  5.6   -4.1  
241.1 CHO-Post  0  913.1  -33.4
262.7 BCAA-Pre   0   -9.7  
1154.2 BCAA-Post    0  -946.5
253.0 PLAC-Pre      0  
207.7 PLAC-Post       0
Critical difference = 255.26      
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Table G-19 Tukey HSD multiple comparison test of the RPE within-subjects effect        
MEANS   0CHO 15CHO 30CHO 45CHO 60CHO 75CHO 90CHO 0BCAA 15BCAA 30BCAA 45BCAA 60BCAA 75BCAA 90BCAA
10.56 0CHO 0        0.33       
13.11 15CHO   0        0.00      
14.56 30CHO     0        0.44     
15.56 45CHO      0        -0.45    
16.22 60CHO       0        -0.66   
16.33 75CHO        0        -1.11  
16.56 90CHO         0        -1.45
10.89 0BCAA          0       
13.11 15BCAA            0      
15.00 30BCAA             0     
15.11 45BCAA              0    
15.56 60BCAA               0   
15.22 75BCAA                0  
15.11 90BCAA                 0
11.22 0PLAC 0.66        0.33       
13.00 15PLAC   -0.11        -0.11      
14.89 30PLAC     0.33        -0.11     
15.33 45PLAC      -0.23        0.22    
15.89 60PLAC       -0.33        0.33   
17.11 75PLAC        0.78        1.89  
18.00 90PLAC         1.44        2.89
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APPENDIX H: RAW DATA 
 
Table H-1 Demographic raw data    
height weight age BMI bodyfat vo2relative vo2absolute 
68.0 73.6 21 24.62 17.6 36.5 2.69 
70.0 91.9 20 29.01 26.1 37.2 3.42 
68.0 75.45 21 25.24 16.2 35.2 2.66 
70.0 63.5 20 20.04 8.0 40.3 2.56 
73.0 91.4 20 26.53 24.0 36.0 3.29 
70.5 76.8 29 23.9 16.2 38.2 2.93 
67.0 91.5 24 31.52 25.4 34.4 3.15 
75.0 120.9 21 33.24 28.9 32.5 3.93 
70.5 72.5 18 22.56 14.3 36.0 2.61 
 
Table H-2 Dietary raw data       
         
CHO Trial                 
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 
Calories     CHO (g)     Protein (g)     
2344.9 2340 1044 228.9 213 73.71 64.4 100.5 28.99 
1657.7 1657.7 595 127.6 127.6 77.2 70.9 70.9 27.6 
1960.7 2656.2 1631.7 154.8 223.9 169.9 49.8 77.7 41.6 
1435 1165.5 1849 191.9 148.6 253.3 45.4 37.7 57.2 
2088.4 2494.7 2877 370.5 390.5 402.5 114.5 73.8 97.7 
1047.8 892.5 1240.5 136.4 127.7 149.6 62.5 33 42.1 
2652.2 3439 2035 411 431.4 486.3 63.1 158.9 25.1 
1398.5 1341 2115 164.6 150.3 230.5 55.9 55.3 84 
3015.5 3015.5 3015.5 503.2 503.2 503.2 85.6 85.6 85.6 
Fat (g)     Vit. C (mg)     Vit. E (IU)     
26 77 16.16 16 48.3 0.16 10 16.7 10.78 
97.2 97.2 17.8 23 23 53.6 14.6 14.6 12.99 
56.5 65 10.9 25.6 34.6 13 10 10 10.01 
58.5 47.8 75.7 0.96 3.3 1.3 13.3 12.9 13.8 
19.6 54.3 38.9 150.4 142.2 65 13.1 15.1 11.1 
28.3 28.4 55 10 44.9 47.8 13.6 11 13.6 
65.8 125.9 12.9 27.6 26.9 12 10.4 16.9 10.6 
59.6 59.2 99.5 63.9 55.3 29.4 15.1 11.8 10.1 
73.4 73.4 73.4 124 124 124 19.6 19.6 19.6 
                  
BCAA Trial                 
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 
Calories     CHO (g)     Protein (g)     
2344.9 2340 1044 228.9 213 73.71 64.4 100.5 28.99 
913.4 913.4 463.7 82.4 82.4 64.7 51.8 51.8 28.1 
1783.7 2458.7 2051.3 204.2 277.7 253.5 30.9 76.2 38.4 
1435 1165.5 1849 191.9 148.6 253.3 45.4 37.7 57.2 
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2060.2 1850 2395.7 326.9 314.2 315.6 67.7 69.2 77.8 
1047.8 892.5 1240.5 136.4 127.7 149.6 62.5 33 42.1 
2652.2 3439 2035 411 431.4 486.3 63.1 158.9 25.1 
1078.4 899 1400 70.1 60.8 119 48.2 34.7 53 
3015.5 3015.5 3015.5 503.2 503.2 503.2 85.6 85.6 85.6 
Fat (g)     Vit. C (mg)     Vit. E (IU)     
26 77 16.16 16 48.3 0.16 10 16.7 10.78 
41.7 41.7 10.1 14.3 14.3 32 13.03 13.03 10.1 
69 51.3 32.4 0 45.6 45.1 10 12.8 10.8 
58.5 47.8 75.7 0.96 3.3 1.3 13.3 12.9 13.8 
59.6 42.7 62.1 10.9 151.5 165.5 13.9 13.4 12.9 
28.3 28.4 55 10 44.9 47.8 13.6 11 13.6 
65.8 125.9 12.9 27.6 26.9 12 10.4 16.9 10.6 
70.7 57.8 79 49.5 36.9 27.6 16.4 11.5 14.3 
73.4 73.4 73.4 124 124 124 19.6 19.6 19.6 
                  
PLAC Trial                 
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 
Calories     CHO (g)     Protein (g)     
2344.9 2340 1044 228.9 213 73.71 64.4 100.5 28.99 
1657.7 1657.7 595 127.6 127.6 77.2 70.9 70.9 27.6 
1960.7 881.5 1420.4 154.8 104.2 188.5 49.8 80.9 111.4 
1435 1165.5 1849 191.9 148.6 253.3 45.4 37.7 57.2 
2088.4 2494.7 2877 370.5 390.5 402.5 114.5 73.8 97.7 
1047.8 892.5 1240.5 136.4 127.7 149.6 62.5 33 42.1 
1582 2297.6 2035 112.1 383.2 486.3 98.3 81 25.1 
1224.7 661.7 1358 108.7 55.7 133.5 69.4 25.2 66.8 
3015.5 3015.5 3015.5 503.2 503.2 503.2 85.6 85.6 85.6 
Fat (g)     Vit. C (mg)     Vit. E (IU)     
26 77 16.16 16 48.3 0.16 10 16.7 10.78 
97.2 97.2 17.8 23 23 53.6 14.6 14.6 12.99 
56.5 14.6 25.6 25.6 16.7 90.8 10 11.4 15.99 
58.5 47.8 75.7 0.96 3.3 1.3 13.3 12.9 13.8 
19.6 54.3 38.9 150.4 142.2 65 13.1 15.1 11.1 
28.3 28.4 55 10 44.9 47.8 13.6 11 13.6 
80.5 56 12.9 20.2 33 12 15.1 10 10.6 
58 38.4 63.1 38.8 34.6 34.8 12.5 11.5 10.8 
73.4 73.4 73.4 124 124 124 19.6 19.6 19.6 
 
 
Table H-3 CK raw data  
    Trial   
  CHO BCAA PLACEBO
        
Pre 97.89 92.65 82.73 
Post 155.64 125.99 135.62 
Post-4 178.14 130.77 209.22 
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Post-24 290.26 131.23 495.88 
Post-48 236.57 119.63 462.23 
        
Pre 201.11 210.15 203.53 
Post 219.65 230.11 289.08 
Post-4 243.28 235.98 365.36 
Post-24 336.34 240.25 867.58 
Post-48 274.81 210.96 652.35 
        
Pre 158.26 145.61 160.25 
Post 161.25 153.39 170.85 
Post-4 190.25 201.65 266.80 
Post-24 225.47 200.65 525.52 
Post-48 201.22 187.99 479.36 
        
Pre 82.40 88.00 92.95 
Post 100.41 99.10 110.23 
Post-4 125.70 106.68 219.56 
Post-24 200.12 136.36 479.03 
Post-48 145.62 125.25 301.92 
        
Pre 107.61 104.32 116.25 
Post 130.08 121.83 153.85 
Post-4 260.77 186.76 246.31 
Post-24 350.34 210.57 510.26 
Post-48 248.22 115.29 268.96 
        
Pre 120.68 115.51 126.30 
Post 167.98 152.61 315.55 
Post-4 364.82 298.36 374.43 
Post-24 425.63 300.60 496.36 
Post-48 336.99 222.73 415.22 
        
Pre 163.95 188.00 185.89 
Post 185.01 210.61 272.60 
Post-4 320.76 251.81 509.60 
Post-24 615.44 264.50 1406.25 
Post-48 456.65 246.84 1031.76 
        
Pre 167.11 191.24 183.09 
Post 226.12 210.56 284.35 
Post-4 320.37 290.74 597.60 
Post-24 462.31 369.36 836.79 
Post-48 385.58 301.45 593.51 
        
Pre 146.87 170.53 136.36 
Post 348.49 172.18 216.88 
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Post-4 366.99 203.66 370.56 
Post-24 333.63 199.21 500.14 
Post-48 321.07 192.29 342.36 
 
 
Table H-4 LDH raw data  
    Trial   
  CHO BCAA PLACEBO
        
Pre 120.2 135.45 124.14 
Post 155.2 163.76 181.27 
Post-4 193.5 163.17 235.35 
Post-24 149.2 153.88 152.46 
Post-48 150.1 159.44 148.58 
        
Pre 171.1 161.27 158.20 
Post 182.5 169.15 175.79 
Post-4 205.6 169.18 211.23 
Post-24 175.2 173.95 171.26 
Post-48 168.2 164.63 164.27 
        
Pre 191.25 185.14 192.56 
Post 209.25 200.00 231.68 
Post-4 231.17 215.64 250.33 
Post-24 216.35 216.33 235.97 
Post-48 201.53 191.67 214.52 
        
Pre 153.2 149.63 148.41 
Post 159.2 154.74 155.23 
Post-4 190.32 161.07 220.32 
Post-24 155.1 144.64 149.03 
Post-48 152.1 151.07 148.41 
        
Pre 90.96 93.63 95.62 
Post 99.20 104.52 110.52 
Post-4 121.64 103.21 142.25 
Post-24 105.20 98.28 126.99 
Post-48 94.2 96.32 124.24 
        
Pre 133.76 129.20 119.98 
Post 141.74 145.41 159.61 
Post-4 180.96 136.29 178.52 
Post-24 150.26 151.82 135.24 
Post-48 144.30 133.76 133.47 
        
Pre 92.34 95.66 85.49 
Post 110.23 108.52 257.38 
 99
Post-4 142.54 121.22 271.22 
Post-24 99.89 111.75 125.36 
Post-48 90.25 98.25 100.01 
        
Pre 207.19 199.24 215.64 
Post 239.54 225.28 246.62 
Post-4 257.38 236.30 275.33 
Post-24 232.44 218.29 239.74 
Post-48 217.67 206.35 220.20 
        
Pre 150.13 157.90 153.17 
Post 213.63 180.39 261.17 
Post-4 234.93 160.92 304.56 
Post-24 185.51 160.41 233.63 
Post-48 164.11 157.06 195.56 
 
 
Table H-5 Leg extension/flexion raw data    
  CHO   BCAA   PLACEBO   
  Extension Flexion Extension Flexion Extension Flexion 
              
Pre 152.1 105.6 153.3 110.7 152.8 114.5 
Post 87.8 82.2 90.6 83.1 84.4 83.0 
Post-4 112.9 81.9 113.4 80.6 100.8 80.2 
Post-24 115.2 81.7 109.5 82.9 104.6 77.7 
Post-48 112.7 85.4 118.4 108.6 102.1 75.2 
              
Pre 165.6 170.2 166.2 165.2 163.8 166.8 
Post 96.5 104.7 142.4 139.05 141.2 136.4 
Post-4 126.1 106.8 169.6 138.9 165.3 131.2 
Post-24 126.4 111.5 160.5 140.13 167.4 119.9 
Post-48 123.2 100.7 164.3 143.3 169.8 120.8 
              
Pre 132.2 98.7 128.9 100.1 135.3 95.3 
Post 113.2 88.5 110.5 84.1 108.5 90.1 
Post-4 120.2 92.3 125.6 97.6 117.5 85.2 
Post-24 115.6 89.2 120.1 95.9 107.5 84.3 
Post-48 119.5 93.5 126.3 97.5 109.5 90.2 
              
Pre 147.1 107.6 142.5 105.9 144.3 105.5 
Post 129.9 103.6 105.1 79.6 86.6 65.6 
Post-4 149.4 90.4 115.9 81.8 92.3 69.8 
Post-24 105.5 74.2 114.3 78.9 97.9 81.6 
Post-48 108.0 78.0 114.2 82.5 101.1 80.4 
              
Pre 174.1 132.5 171.2 130.9 170.2 136.9 
Post 132.43 124.5 99.2 107.7 102.6 102.3 
 100
Post-4 115.62 91.2 159.2 150.9 110.3 107.5 
Post-24 121.2 92.2 129.3 101.7 136.7 93.9 
Post-48 126.8 90.9 127.6 120.2 140.1 94.7 
              
Pre 146.0 117.2 147.9 120.8 143.6 118.2 
Post 81.9 83.2 101.3 95.5 88.6 84.5 
Post-4 103.9 77.9 115.5 98.3 109.1 90.3 
Post-24 113.1 83.9 105.1 109.7 106.3 86.2 
Post-48 109.7 75.8 136.3 112.8 116.5 87.8 
              
Pre 179.1 110.1 176.1 113.7 179.3 110.9 
Post 166.6 113.6 107.9 95.9 112.5 83.6 
Post-4 177.2 111.2 123.5 76.7 130.1 86.2 
Post-24 175.3 115.3 130.1 83.6 129.3 85.1 
Post-48 140.3 88.1 131.6 113.9 130.3 87.2 
              
Pre 203.2 148.4 198.7 147.8 205.3 159.8 
Post 118.2 95.2 127.45 103.7 116.4 118.0 
Post-4 122.6 98.4 147.63 104.0 127.1 111.4 
Post-24 138.6 109.0 155.95 107.2 133.3 105.0 
Post-48 135.6 103.5 161.08 113.3 131.6 105.2 
              
Pre 136.3 89.5 132.2 86.8 130.3 87.8 
Post 81.7 74.1 89.3 74.6 80.1 69.2 
Post-4 93.4 68.1 96.0 67.5 96.5 68.3 
Post-24 90.3 71.2 95.3 70.0 96.7 69.0 




Rate of perceived soreness raw 
data 
    Trial   
  CHO BCAA PLACEBO 
        
Pre 1 1   
Post 1 1 1 
Post-4 1 1 1 
Post-24 3 3 4 
Post-48 2 2 2 
        
Pre 1 1 1 
Post 1 1 1 
Post-4 1 1 1 
Post-24 3 1 4 
Post-48 2 1 2 
        
Pre 1 1 1 
Post 1 1 1 
 101
Post-4 1 1 1 
Post-24 2 1 3 
Post-48 1 1 1 
        
Pre 1 1 1 
Post 1 1 1 
Post-4 1 1 1 
Post-24 1 1 2 
Post-48 1 1 1 
        
Pre 1 1 1 
Post 1 1 1 
Post-4 1 1 1 
Post-24 4 1 2 
Post-48 1 1 1 
        
Pre 1 1 1 
Post 1 1 1 
Post-4 1 1 1 
Post-24 3 1 2 
Post-48 1 1 2 
        
Pre 1 1 1 
Post 1 1 1 
Post-4 1 1 1 
Post-24 2 1 2 
Post-48 1 1 1 
        
Pre 1 1 1 
Post 1 1 1 
Post-4 1 1 1 
Post-24 1 1 2 
Post-48 1 1 2 
        
Pre 1 1 1 
Post 1 1 1 
Post-4 1 1 1 
Post-24 2 2 3 
Post-48 2 1 2 
 
 
Table H-7 Time trial raw data 
  Trial   
CHO BCAA PLACEBO 
5.2 4.8 4.0 
4.4 4.3 3.6 
4.1 4.2 3.7 
 102
4.5 4.8 3.9 
5.8 5.4 4.9 
4.8 4.3 3.9 
4.2 4.1 3.7 
4.4 4.1 3.8 
4.0 3.6 3.8 
 
 
Table H-8 RPE raw data     
      Time (hr:min)       
0:00 0:15 0:30 0:45 1:00 1:15 1:30 
CHO             
11 13 16 17 18 19 20 
12 15 16 16 17 18 19 
11 13 15 16 16 16 17 
13 15 16 17 18 19 18 
10 12 13 14 15 14 14 
11 14 13 13 13 12 13 
7 12 14 15 16 17 17 
9 12 15 16 17 16 15 
11 12 13 16 16 16 16 
              
BCAA             
9 11 13 13 13 13 14 
9 13 15 15 16 16 16 
11 13 15 15 16 15 15 
14 16 18 19 19 18 18 
13 15 16 16 17 16 16 
13 14 15 14 14 14 14 
7 11 15 17 18 18 17 
11 13 15 14 13 12 11 
11 12 13 13 14 15 15 
              
PLAC             
13 13 13 13 15 17 17 
11 12 15 15 15 16 18 
11 13 15 15 16 17 18 
15 16 17 18 18 19 19 
9 13 15 16 17 18 19 
13 14 17 17 16 17 18 
9 11 12 13 14 16 18 
9 13 17 18 18 19 19 






Table H-9 VO2 and ventilation raw data       
    VO2 (absolute)     VO2 (relative)     Ventilation   
Time CHO BCAA PLAC CHO BCAA PLAC CHO BCAA PLAC 
0:00 1.53 1.45 1.54 20.8 18.6 20.1 29.85 28.92 29.83 
0:15 1.77 1.85 1.79 23.9 23.8 23.4 46.70 42.46 40.44 
0:30 1.77 1.68 1.49 25.0 21.6 19.5 44.38 36.98 37.17 
0:45 1.62 1.51 1.56 22.0 19.4 20.4 36.92 30.45 31.92 
1:00 1.50 1.56 1.49 20.3 20.1 19.5 34.69 31.77 30.95 
1:15 1.34 1.48 1.51 20.6 19.1 19.7 29.03 28.19 29.51 
1:30 1.35 1.56 1.51 21.8 20.0 19.7 32.8 29.74 29.5 
                    
0:00 1.91 1.72 1.64 21.0 18.7 18.1 39.77 36.72 39.43 
0:15 1.98 1.93 1.91 21.8 21.0 21.0 48.61 48.49 48.10 
0:30 1.98 1.92 1.98 21.8 21.0 21.8 46.58 49.25 44.10 
0:45 1.92 1.72 1.80 21.2 18.8 19.8 40.29 38.57 39.75 
1:00 2.02 1.69 1.58 22.3 18.4 17.5 42.01 38.44 37.68 
1:15 2.05 1.73 1.65 22.6 18.7 18.2 44.47 36.56 35.23 
1:30 2.08 1.67 1.80 22.9 18.2 19.8 44.03 37.19 40.62 
                    
0:00 1.38 1.43 1.36 18.3 19.0 18.0 29.85 30.56 32.56 
0:15 1.42 1.44 1.41 18.8 19.1 18.7 35.65 39.12 42.25 
0:30 1.41 1.39 1.42 18.7 18.4 18.8 34.61 36.75 33.99 
0:45 1.36 1.31 1.39 18.0 17.4 18.4 36.25 34.88 39.62 
1:00 1.43 1.36 1.45 18.9 18.0 19.2 37.55 40.01 43.36 
1:15 1.38 1.41 1.29 18.3 18.7 17.1 38.00 38.54 42.13 
1:30 1.40 1.40 1.35 18.5 18.5 17.9 40.01 37.52 38.65 
                    
0:00 1.47 1.51 1.58 23.1 22.8 24.7 30.02 30.06 32.93 
0:15 1.51 1.65 1.51 23.7 24.9 23.7 38.40 38.45 33.05 
0:30 1.38 1.55 1.70 21.6 23.3 26.5 34.48 36.09 35.15 
0:45 1.48 1.68 1.44 23.2 25.3 22.5 32.33 33.10 29.47 
1:00 1.57 1.43 1.32 24.7 21.6 20.7 31.23 29.76 25.90 
1:15 1.59 1.44 1.47 24.9 21.6 23.0 34.63 29.69 29.49 
1:30 1.53 1.43 1.46 23.9 21.6 22.9 32.27 29.60 29.38 
                    
0:00 1.75 1.58 1.85 19.5 17.4 19.7 38.73 31.58 35.77 
0:15 2.00 2.02 2.05 22.2 22.3 21.7 47.31 42.39 42.76 
0:30 1.91 1.99 2.03 21.3 21.9 21.6 45.45 41.08 42.67 
0:45 1.57 1.95 1.77 17.5 20.64 18.8 42.65 40.64 37.17 
1:00 1.96 1.85 1.89 21.8 20.4 20.1 46.41 40.26 41.53 
1:15 1.80 1.83 1.59 20.0 20.1 16.8 48.53 44.01 36.22 
1:30 1.81 1.89 1.61 20.1 20.8 17.1 41.19 37.22 33.67 
                    
0:00 1.66 1.49 1.67 21.7 19.9 21.8 38.56 41.89 39.57 
0:15 1.84 1.60 1.73 24.4 21.3 22.5 49.32 42.04 46.26 
0:30 1.78 1.68 1.77 23.6 22.4 23.1 46.20 39.99 44.98 
0:45 1.71 1.52 1.70 22.7 20.3 22.1 40.26 39.62 45.33 
 104
1:00 1.67 1.70 1.76 22.2 22.6 23.0 38.76 40.71 47.02 
1:15 1.62 1.70 1.75 21.5 22.6 22.8 37.33 39.46 47.02 
1:30 1.60 1.85 1.67 21.3 24.6 21.8 32.31 47.37 46.02 
                    
0:00 1.74 1.79 1.52 20.1 20.0 17.1 33.49 30.96 32.35 
0:15 2.05 2.12 1.92 22.7 23.8 21.6 41.66 46.50 43.21 
0:30 1.93 2.19 2.23 22.3 24.5 25.1 44.34 51.04 49.92 
0:45 1.92 2.12 1.96 22.2 23.8 22.1 40.88 45.05 42.24 
1:00 1.92 1.97 2.08 22.1 22.2 23.5 37.19 51.73 46.10 
1:15 1.98 2.08 2.02 22.8 23.3 22.7 37.95 40.47 41.57 
1:30 1.75 2.09 1.91 20.2 23.4 21.5 35.20 43.32 38.20 
                    
0:00 2.09 1.95 2.32 17.5 17.2 19.2 42.70 42.27 49.03 
0:15 2.32 2.31 2.60 19.5 20.3 21.4 52.90 52.42 63.65 
0:30 2.15 2.00 2.40 18.0 17.6 19.8 47.13 44.59 58.57 
0:45 2.55 2.10 2.40 21.2 17.8 19.8 56.55 56.25 58.57 
1:00 2.34 2.50 2.57 19.6 20.9 20.8 55.85 58.74 62.25 
1:15 2.40 2.50 2.42 19.8 20.9 20.0 49.20 56.99 57.95 
1:30 2.51 2.56 2.61 20.8 21.3 21.5 48.65 60.55 64.01 
                    
0:00 1.58 1.46 1.49 22.2 21.0 21.1 23.52 27.27 26.94 
0:15 1.91 1.54 1.43 26.8 22.2 20.4 31.58 27.53 29.05 
0:30 2.03 1.61 1.68 28.6 23.1 23.8 39.89 27.17 33.74 
0:45 2.02 1.67 1.50 28.4 23.9 21.4 39.18 32.48 29.04 
1:00 1.91 1.63 1.67 26.8 23.4 23.8 36.53 31.05 32.65 
1:15 2.06 1.44 1.73 28.9 20.7 24.7 36.78 29.91 30.94 
1:30 2.11 1.50 1.58 29.7 23.8 22.5 41.10 31.85 30.01 
 
 
Table H-10 HR raw data     
      Time (hr:min)       
0:00 0:15 0:30 0:45 1:00 1:15 1:30 
CHO             
  123.00   157.00   157.00   166.00   170.00   162.00   169.00 
  123.00   149.00   152.00   144.00   146.00   151.00   149.00 
  125.00   140.00   141.00   146.00   144.00   150.00   148.00 
  121.00   144.00   149.00   151.00   155.00   153.00   160.00 
  121.00   124.00   127.00   121.00   131.00   129.00   136.00 
  131.00   169.00   166.00   157.00   154.00   154.00   158.00 
  122.00   151.00   159.00   152.00   156.00   158.00   156.00 
  155.00   177.00   182.00   174.00   168.00   163.00   168.00 
  124.00   156.00   177.00   173.00   176.00   176.00   181.00 
              
BCAA             
  128.00   156.00   161.00   150.00   153.00   152.00   152.00 
  113.00   135.00   141.00   138.00   141.00   145.00   150.00 
  121.00   135.00   150.00   149.00   149.00   155.00   156.00 
 105
  132.00   153.00   145.00   133.00   134.00   161.00   150.00 
  114.00   132.00   135.00   136.00   141.00   150.00   151.00 
  104.00   154.00   166.00   163.00   168.00   167.00   168.00 
  122.00   148.00   154.00   155.00   162.00   159.00   161.00 
  144.00   154.00   169.00   177.00   154.00   168.00   158.00 
  127.00   148.00   154.00   159.00   157.00   167.00   167.00 
              
PLAC             
  118.00   150.00   158.00   153.00   152.00   150.00   158.00 
  113.00   126.00   134.00   125.00   135.00   146.00   141.00 
  130.00   141.00   150.00   148.00   138.00   152.00   145.00 
  138.00   147.00   157.00   155.00   161.00   156.00   163.00 
  110.00   122.00   125.00   126.00   126.00   139.00   140.00 
  131.00   162.00   177.00   160.00   159.00   160.00   161.00 
  115.00   139.00   157.00   156.00   159.00   161.00   156.00 
  159.00   167.00   152.00   183.00   171.00   162.00   168.00 
  131.00   155.00   166.00   165.00   165.00   169.00   170.00 
 
 
Table H-11 RER raw data     
      Time (hr:min)       
0:00 0:15 0:30 0:45 1:00 1:15 1:30 
CHO             
0.87 0.96 0.96 0.86 0.88 0.84 0.84 
1.03 1.00 0.93 0.87 0.88 0.85 0.87 
0.99 0.99 0.97 0.93 0.93 0.9 0.92 
1.11 1.08 1.05 1.01 0.98 0.98 0.99 
0.96 0.97 0.95 0.96 0.97 0.97 0.92 
1.05 1.01 0.98 1.01 1.00 1.00 1.09 
1.00 0.97 0.97 0.92 0.93 0.89 0.86 
0.98 0.99 0.95 0.95 0.94 0.86 0.94 
0.91 0.9 0.93 0.85 0.85 0.82 0.81 
              
BCAA             
0.93 1.02 0.90 0.89 0.87 0.81 0.84 
0.98 0.98 0.91 0.86 0.85 0.87 0.86 
0.92 0.96 0.94 0.9 0.88 0.88 0.88 
0.96 0.97 0.96 0.89 0.84 0.88 0.89 
0.94 0.97 0.97 0.97 0.92 0.98 0.89 
1.06 1.05 1.01 0.96 0.96 0.97 0.97 
0.94 0.94 0.96 0.93 0.89 0.86 0.88 
0.99 0.96 0.92 0.88 0.86 0.87 0.87 
0.97 0.82 0.91 0.85 0.82 0.81 0.83 
              
PLAC             
0.9 0.97 0.92 0.86 0.88 0.84 0.84 
1.05 0.99 0.97 0.86 0.86 0.86 0.87 
 106
0.96 0.96 0.93 0.9 0.89 0.85 0.86 
0.92 0.95 0.89 0.88 0.89 0.86 0.86 
0.87 0.91 0.9 0.88 0.87 0.82 0.84 
1.17 1.10 0.99 0.98 0.96 0.9 0.93 
0.89 0.92 0.93 0.86 0.88 0.81 0.85 
1.02 1.00 0.99 0.99 0.91 0.88 0.88 
0.88 0.87 0.85 0.88 0.85 0.85 0.82 
 
 
Table H-12 Energy Expenditure raw data    
CHO 0:15 VO2 RER Cal/min Cal Total CHO Cal Fat Cal 
  1.77 0.96 8.8323 132.4845 111.287 21.19752 
  1.98 1.00 9.999 149.985 149.985 0 
  1.42 0.99 7.171 107.565 107.565 0 
  1.51 1.08 7.6255 114.3825 114.3825 0 
  2.00 0.97 10.04 150.6 138.552 12.048 
  1.84 1.01 9.292 139.38 139.38 0 
  2.05 0.97 10.291 154.365 142.0158 12.3492 
  2.32 0.99 11.716 175.74 175.74 0 
  1.91 0.9 9.3972 140.958 95.14665 45.81135 
CHO 0:30 1.77 0.96 8.8323 132.4845 111.287 21.19752 
  1.98 0.93 9.8802 148.203 124.4905 23.71248 
  1.41 0.97 7.0782 106.173 97.67916 8.49384 
  1.38 1.05 6.969 104.535 104.535 0 
  1.91 0.95 9.5309 142.9635 120.0893 22.87416 
  1.78 0.98 8.9356 134.034 123.3113 10.72272 
  1.93 0.97 9.6886 145.329 133.7027 11.62632 
  2.15 0.95 10.7285 160.9275 135.1791 25.7484 
  2.03 0.93 10.1297 151.9455 127.6342 24.31128 
CHO 0:45 1.62 0.86 7.8732 118.098 59.87569 58.22231 
  1.92 0.87 9.3312 139.968 70.96378 69.00422 
  1.36 0.93 6.7864 101.796 85.50864 16.28736 
  1.48 1.01 7.474 112.11 112.11 0 
  1.57 0.96 7.8343 117.5145 98.71218 18.80232 
  1.71 1.01 8.6355 129.5325 129.5325 0 
  1.92 0.92 9.4464 141.696 95.6448 46.0512 
  2.55 0.95 12.7245 190.8675 160.3287 30.5388 
  2.02 0.85 9.8172 147.258 74.65981 72.59819 
CHO 1:00 1.50 0.88 7.38 110.7 74.7225 35.9775 
  2.02 0.88 9.9384 149.076 100.6263 48.4497 
  1.43 0.93 7.1357 107.0355 89.90982 17.12568 
  1.57 0.98 7.8814 118.221 108.7633 9.45768 
  1.96 0.97 9.8392 147.588 135.781 11.80704 
  1.67 1.00 8.4335 126.5025 126.5025 0 
  1.92 0.93 9.5808 143.712 120.7181 22.99392 
  2.34 0.94 11.6766 175.149 147.1252 28.02384 
  1.91 0.85 9.2826 139.239 70.59417 68.64483 
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CHO 1:15 1.34 0.84 6.5124 97.686 49.5268 48.1592 
  2.05 0.85 9.963 149.445 75.76862 73.67639 
  1.38 0.9 6.7896 101.844 68.7447 33.0993 
  1.59 0.98 7.9818 119.727 110.1488 9.57816 
  1.80 0.97 9.036 135.54 124.6968 10.8432 
  1.62 1.00 8.181 122.715 112.8978 9.8172 
  1.98 0.89 9.7416 146.124 98.6337 47.4903 
  2.40 0.86 11.664 174.96 88.70472 86.25528 
  2.06 0.82 9.888 148.32 49.53888 98.78112 
CHO 1:30 1.35 0.84 6.561 98.415 49.89641 48.5186 
  2.08 0.87 10.1088 151.632 76.87742 74.75458 
  1.40 0.92 6.888 103.32 69.741 33.579 
  1.53 0.99 7.7265 115.8975 115.8975 0 
  1.81 0.92 8.9052 133.578 90.16515 43.41285 
  1.60 1.09 8.08 121.2 121.2 0 
  1.75 0.86 8.505 127.575 64.68053 62.89448 
  2.51 0.94 12.5249 187.8735 157.8137 30.05976 
  2.11 0.81 10.128 151.92 50.74128 101.1787 
BCAA 0:15 1.85 1.02 9.3425 140.1375 140.1375 0 
  1.93 0.98 9.6886 145.329 133.7027 11.62632 
  1.44 0.96 7.1856 107.784 90.53856 17.24544 
  1.65 0.97 8.283 124.245 114.3054 9.9396 
  2.02 0.97 10.1404 152.106 139.9375 12.16848 
  1.60 1.05 8.08 121.2 121.2 0 
  2.12 0.94 10.5788 158.682 133.2929 25.38912 
  2.31 0.96 11.5269 172.9035 145.2389 27.66456 
  1.54 0.82 7.392 110.88 37.03392 73.84608 
BCAA 0:30 1.68 0.9 8.2656 123.984 83.6892 40.2948 
  1.92 0.91 9.4464 141.696 95.6448 46.0512 
  1.39 0.94 6.9361 104.0415 87.39486 16.64664 
  1.55 0.96 7.7345 116.0175 97.4547 18.5628 
  1.99 0.97 9.9898 149.847 137.8592 11.98776 
  1.68 1.01 8.484 127.26 127.26 0 
  2.19 0.96 10.9281 163.9215 137.6941 26.22744 
  2.00 0.92 9.84 147.6 99.63 47.97 
  1.61 0.91 7.9212 118.818 80.20215 38.61585 
BCAA 0:45 1.51 0.89 7.4292 111.438 75.22065 36.21735 
  1.72 0.86 8.3592 125.388 63.57172 61.81628 
  1.31 0.9 6.4452 96.678 65.25765 31.42035 
  1.68 0.89 8.2656 123.984 83.6892 40.2948 
  1.95 0.97 9.789 146.835 135.0882 11.7468 
  1.52 0.96 7.5848 113.772 95.56848 18.20352 
  2.12 0.93 10.5788 158.682 133.2929 25.38912 
  2.10 0.88 10.332 154.98 104.6115 50.3685 
  1.67 0.85 8.1162 121.743 61.7237 60.0193 
BCAA 1:00 1.56 0.87 7.5816 113.724 57.65807 56.06593 
  1.69 0.85 8.2134 123.201 62.46291 60.73809 
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  1.36 0.88 6.6912 100.368 67.7484 32.6196 
  1.43 0.84 6.9498 104.247 52.85323 51.39377 
  1.85 0.92 9.102 136.53 92.15775 44.37225 
  1.70 0.96 8.483 127.245 106.8858 20.3592 
  1.97 0.89 9.6924 145.386 98.13555 47.25045 
  2.50 0.86 12.15 182.25 92.40075 89.84925 
  1.63 0.82 7.824 117.36 39.19824 78.16176 
BCAA 1:15 1.48 0.81 7.104 106.56 35.59104 70.96896 
  1.73 0.87 8.4078 126.117 63.94132 62.17568 
  1.41 0.88 6.9372 104.058 70.23915 33.81885 
  1.44 0.88 7.0848 106.272 71.7336 34.5384 
  1.83 0.98 9.1866 137.799 126.7751 11.02392 
  1.70 0.97 8.534 128.01 117.7692 10.2408 
  2.08 0.86 10.1088 151.632 76.87742 74.75458 
  2.50 0.87 12.15 182.25 92.40075 89.84925 
  1.44 0.81 6.912 103.68 34.62912 69.05088 
BCAA 1:30 1.56 0.84 7.5816 113.724 57.65807 56.06593 
  1.67 0.86 8.1162 121.743 61.7237 60.0193 
  1.40 0.88 6.888 103.32 69.741 33.579 
  1.43 0.89 7.0356 105.534 71.23545 34.29855 
  1.89 0.89 9.2988 139.482 94.15035 45.33165 
  1.85 0.97 9.287 139.305 128.1606 11.1444 
  2.09 0.88 10.2828 154.242 104.1134 50.12865 
  2.56 0.87 12.4416 186.624 94.61837 92.00563 
  1.50 0.83 7.29 109.35 55.44045 53.90955 
PLAC 0:15 1.79 0.97 8.9858 134.787 124.004 10.78296 
  1.91 0.99 9.6455 144.6825 144.6825 0 
  1.41 0.96 7.0359 105.5385 88.65234 16.88616 
  1.51 0.95 7.5349 113.0235 94.93974 18.08376 
  2.05 0.91 10.086 151.29 102.1208 49.16925 
  1.73 1.10 8.7365 131.0475 131.0475 0 
  1.92 0.92 9.4464 141.696 95.6448 46.0512 
  2.60 1.00 13.13 196.95 196.95 0 
  1.43 0.87 6.9498 104.247 52.85323 51.39377 
PLAC 0:30 1.49 0.92 7.3308 109.962 74.22435 35.73765 
  1.98 0.97 9.9396 149.094 137.1665 11.92752 
  1.42 0.93 7.0858 106.287 89.28108 17.00592 
  1.70 0.89 8.364 125.46 84.6855 40.7745 
  2.03 0.9 9.9876 149.814 101.1245 48.68955 
  1.77 0.99 8.9385 134.0775 134.0775 0 
  2.23 0.93 11.1277 166.9155 140.209 26.70648 
  2.40 0.99 12.12 181.8 181.8 0 
  1.68 0.85 8.1648 122.472 62.0933 60.3787 
PLAC 0:45 1.56 0.86 7.5816 113.724 57.65807 56.06593 
  1.80 0.86 8.748 131.22 66.52854 64.69146 
  1.39 0.9 6.8388 102.582 69.24285 33.33915 
  1.44 0.88 7.0848 106.272 71.7336 34.5384 
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  1.77 0.88 8.7084 130.626 88.17255 42.45345 
  1.70 0.98 8.534 128.01 117.7692 10.2408 
  1.96 0.86 9.5256 142.884 72.44219 70.44181 
  2.40 0.99 12.12 181.8 181.8 0 
  1.50 0.88 7.38 110.7 74.7225 35.9775 
PLAC 1:00 1.49 0.88 7.3308 109.962 74.22435 35.73765 
  1.58 0.86 7.6788 115.182 58.39727 56.78473 
  1.45 0.89 7.134 107.01 72.23175 34.77825 
  1.32 0.89 6.4944 97.416 65.7558 31.6602 
  1.89 0.87 9.1854 137.781 69.85497 67.92603 
  1.76 0.96 8.7824 131.736 110.6582 21.07776 
  2.08 0.88 10.2336 153.504 103.6152 49.8888 
  2.57 0.91 12.6444 189.666 128.0246 61.64145 
  1.67 0.85 8.1162 121.743 61.7237 60.0193 
PLAC 1:15 1.51 0.84 7.3386 110.079 55.81005 54.26895 
  1.65 0.86 8.019 120.285 60.9845 59.30051 
  1.29 0.85 6.2694 94.041 47.67879 46.36221 
  1.47 0.86 7.1442 107.163 54.33164 52.83136 
  1.59 0.82 7.8228 117.342 79.20585 38.13615 
  1.75 0.9 8.61 129.15 87.17625 41.97375 
  2.02 0.81 9.696 145.44 48.57696 96.86304 
  2.42 0.88 11.9064 178.596 120.5523 58.0437 
  1.73 0.85 8.4078 126.117 63.94132 62.17568 
PLAC 1:30 1.51 0.84 7.3386 110.079 55.81005 54.26895 
  1.80 0.87 8.748 131.22 66.52854 64.69146 
  1.35 0.86 6.561 98.415 49.89641 48.5186 
  1.46 0.86 7.0956 106.434 53.96204 52.47196 
  1.61 0.84 7.8246 117.369 59.50608 57.86292 
  1.67 0.93 8.3333 124.9995 104.9996 19.99992 
  1.91 0.85 9.2826 139.239 70.59417 68.64483 
  2.61 0.88 12.8412 192.618 130.0172 62.60085 
  1.58 0.82 7.584 113.76 37.99584 75.76416 
 
 
Table H-13 Glucose raw data    
CHO Pre CHO Post BCAA Pre BCAA Post PLAC Pre PLAC Post
92.1 116.71 111.13 112.69 113.58 85.25 
95.23 106.195 94.57 93.393 96.97 113.58 
82.3 90.35 89.22 90.21 88.95 93.56 
87.31 84.641 84.90 80.53 87.45 89.54 
94.77 105.726 90.48 96.28 94.53 82.82 
92.13 86.36 103.42 89.69 106.83 77.68 
114.88 129.33 114.17 144.69 111.67 122.65 
120.79 119.25 102.10 106.89 124.70 119.99 




Table H-14 BCAA raw data       
    CHO BCAA PLACEBO   CHO BCAA PLACEBO
Leucine Pre 139.1 129.3 144.1 Post 131.5 763.9 111.6 
    142.6 130.3 148.5   129.2 656.5 121.5 
    123.2 145.9 139.9   121.1 803.1 108.9 
    103.0 105.4 115.2   100.0 674.1 89.9 
    129.0 145.1 135.4   126.9 905.3 112.9 
    135.8 128.1 141.1   123.8 595.1 107.8 
    104.3 110.0 108.7   99.6 632.8 86.0 
    171.5 162.7 178.3   156.7 608.9 132.1 
    155.7 149.8 161.2   150.2 856.7 129.1 
Isoleucine Pre 42.2 46.5 52.3 Post 41.1 516.1 43.0 
    83.6 87.5 91.0   79.5 635.2 59.3 
    61.0 68.4 68.4   58.2 462.2 63.2 
    59.3 63.0 58.4   56.2 501.3 48.7 
    43.1 45.8 52.9   39.0 601.8 38.7 
    75.9 69.3 76.3   61.3 429.8 54.0 
    66.0 88.6 63.6   60.2 701.3 50.6 
    92.9 88.0 89.3   90.3 763.1 69.4 
    72.8 65.2 75.6   67.9 623.8 58.6 
Valine Pre 265.8 268.3 251.3 Post 248.9 1136.5 215.5 
    271.1 263.1 259.6   234.6 1052.4 203.5 
    217.1 251.4 210.3   210.5 1261.6 169.3 
    262.5 270.2 263.7   258.6 989.2 225.0 
    218.9 235.6 209.8   210.9 1323.9 165.0 
    220.0 214.3 221.9   199.9 1295.8 184.5 
    281.2 285.3 273.7   266.1 916.6 239.7 
    302.3 311.5 299.8   287.4 1018.7 241.9 
    278.6 267.1 292.6   261.3 1398.6 228.5 
 
 
Table H-15 Hemoglobin and hematocrit raw data    
Trial Pre Post Post-4 Post-24 Post-48 Pre Post Post-4 Post-24 Post-48
CHO 14.77 15.62 15.23 15.57 16.18 39.5 44 41.5 41.66 40.66 
  17.2 17.9 17.3 17.5 16.9 44 46 44 44.5 43 
  15.42 16.28 16.06 16.14 15.93 46.5 49.5 47.66 47 46.66 
  16.22 16.29 16.44 16.27 15.74 46 47.5 46.5 46 45.5 
  15.29 15.4 15.6 16.02 15.99 42 43 42.25 44 44 
  15.29 15.69 15.98 15.56 15.2 44.5 47.66 46.33 44.5 43.33 
  17.85 19 18.82 18.52 17.99 45 47.2 45.5 45.33 45 
  13.52 14.4 14.01 14.08 14.12 41.5 45.5 40.5 41.75 43 
  16.22 16.9 16.54 16.27 15.74 46 49.25 46.5 46 45.5 
                      
BCAA 14.05 15.43 13.02 14.56 14.56 42 45.66 40.33 43.66 44 
  15.86 16.06 16.01 15.75 16 47.75 49 48 47.33 48 
 111
  16.52 17.36 16.31 16.12 16.14 46.25 48 45.66 46.52 43.6 
  14.65 15.03 14.57 14.24 14.75 46 47.75 46 43 45 
  16.19 16.67 16.2 16.04 16.31 48 49.5 47 47.5 48 
  15.65 15.62 14.79 16.03 16.06 44 44.66 42 43.66 43.66 
  18.03 18.13 18.21 17.79 17.89 48 50 49 48.33 48.33 
  13.65 13.58 12.93 13.18 13.52 48.5 49 47.5 46 48 
  14.05 15.43 13.98 14.56 14.56 42 45.5 42.2 42.33 42.25 
                      
PLAC 15.33 15.31 14.39 15.12 15.03 44 45.33 41.25 42.5 43 
  15.07 15.56 14.28 14.73 15.01 44.5 45 40.66 42.5 43.33 
  14.7 14.87 14.69 13.98 14.01 46.33 47.5 46.66 45 44 
  15.36 15.99 16.01 15.61 14.99 44 46 46.5 45.33 43.66 
  17.01 17.34 17.15 16.87 16.99 48.66 51.33 49.33 48.5 47.66 
  14.99 15.34 15.13 14.78 14.82 43 46 45 44.33 42.33 
  18.83 19.88 18.78 19.08 18.57 46 47.5 45.5 45.5 43.66 
  13.35 13.62 13.25 13.62 13.44 45 47.5 46.33 45.5 45.33 
  15.01 14.98 15.03 15.22 14.87 43 44 44.33 42.66 43 
 
 
Table H-16 Plasma volume shifts raw data  
Trial Pre Post Post-4 Post-24 Post-48
CHO / 5.61 2.02 0.18 -5.96 
  / 0.56 -0.58 -0.57 -0.59 
  / 0.96 -1.54 -3.41 -2.86 
  / 2.89 -0.24 -0.31 1.9 
  / 1.71 -1.39 0.1 0.29 
  / 4.53 -0.29 -1.74 -2.11 
  / -1.36 -4.08 -2.89 -0.78 
  / 3.16 -5.88 -3.38 -0.7 
  / 2.91 -0.85 -0.31 1.9 
            
BCAA / -0.82 3.52 0.4 1.2 
  / 1.4 -0.41 -0.21 -0.34 
  / -1.16 -0.03 3.09 -3.64 
  / 1.26 0.55 -3.98 -2.89 
  / 0.22 -2.19 -0.14 -0.74 
  / 1.73 0.89 -3.14 -3.32 
  / 3.68 1.12 2.06 1.49 
  / 1.57 3.35 -1.88 -0.1 
  / -1.17 0.99 -2.73 -2.91 
            
PLAC / 3.23 -0.28 -2.15 -0.38 
  / -2.04 -3.78 -2.4 -2.3 
 112
  / 1.41 0.8 2.07 -0.47 
  / 0.53 1.52 1.44 1.66 
  / 3.59 0.58 0.49 -1.98 
  / 4.7 3.79 4.63 -0.47 
  / -2.12 -0.85 -2.41 -3.87 
  / 3.59 3.8 -0.87 0.08 
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